WO1995009917A1 - Genetically engineered bispecific tetravalent antibodies - Google Patents
Genetically engineered bispecific tetravalent antibodies Download PDFInfo
- Publication number
- WO1995009917A1 WO1995009917A1 PCT/US1994/011411 US9411411W WO9509917A1 WO 1995009917 A1 WO1995009917 A1 WO 1995009917A1 US 9411411 W US9411411 W US 9411411W WO 9509917 A1 WO9509917 A1 WO 9509917A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- antibody
- cells
- encoding
- dna segment
- tetravalent
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Definitions
- This invention relates to the production of bispecific, tetravalent antibodies using recombinant DNA methods.
- the antibody protein is produced at the DNA level and expressed by transfection.
- the resulting antibody has two different specificities, one at the N-terminus and one at the C-terminus.
- This invention may have both therapeutic and immunodiagnostic applications.
- antigens capable of simultaneously binding two different antigens
- antigens may be, for example, a tumor cell antigen and an effector cell such as an activated T cell or functional agent such as a cytotoxin (Flavell et al., (1 991 ) British J. Cancer, 64: 274; Runge et al., (1990) Bioconjugate Chem., 1 : 274).
- tumor cell antigens include carcinoembryonic antigen, a widely-expressed tumor cell marker and Le v antigen expressed on breast, lung and colon carcinomas.
- This provides an effective means to facilitate targeting of these cells and toxins to transformed cells.
- This method has been used to increase cytotoxicity of activated T cells toward human glioma cells (Nitta et al., (1 990) J. Neurosurg., 72: 476-481 ; Nishimura et al., (1992) J. Immunol., 148: 285-291 ) and to target the toxins ricin and vindesine to tumor cells (Embleton et al., (1 991 ) British J. Cancer, 63: 670- 674; Corvalan and Smith, (1 987) Cancer Immunol. Immunother., 24: 127-1 32).
- catalytic antibodies have also been described which may act as highly selective catalysts in biology, chemistry and medicine (Shokat and Schultz, (1 990) Annu. Rev. Immunol. 8: 335-363).
- Bispecific antibodies have been produced using a variety of methods. Univalent fragments of pepsin-treated antibodies of different specificities or of complete antibodies have been chemically linked to produce bispecific antibodies (Raso and Griffin, (1981 ) Cancer Res., 41 : 2073; Glennie et al., (1987) J. Immunol., 139: 2367; Glennie et al., (1988) J. Immunol. 141 : 3662-3670). In addition, fusion of two hybridoma cells yields a hybrid hybridoma called a quadroma which produces some mixed molecules having the specificities of each hybridoma
- FIGURES Figure 1 illustrates the primers and PCR reactions used to generate the anti- dansyl single chain antibody. Primers A and B were used to amplify V H and to incorporate restriction sites and linkers. Primers C and D were used to amplify V L .
- Figure 2 illustrates the construction of the pAH4633 expression vector expressing the heavy chain of the bispecific antibody.
- the PCR generated single chain antibody was subcloned into pSK3461 , an intermediate vector containing a human lgG3 constant region.
- the BamH1 -Sal1 fragment containing the constant region of the SCAB from pSK4629 replaced the same fragment from pAH3617, an anti-dextran V H expression vector to generate pAH4633.
- Figure 3 is a schematic representation of the expected structure of the bispecific antibody.
- An anti-dansyl SCAB was fused to the 3' end of an anti- dextran lgG3 chimeric antibody. The arrows indicate the antigen combining sites.
- Figure 4 indicates a half-life determination of the bispecific antibody. 1 x 10 6 counts of [ 125 l] labeled antibody were injected intraperitoneally into mice in triplicate and whole body counts were measured. The time, in hours, is indicated on the x-axis and the % of cpm remaining is indicated on the y-axis.
- Figure 5 illustrates a high affinity F c receptor binding assay.
- 125 l labeled antibodies were incubated in the presence of varying amounts of excess cold ligand with 2 x 10 6 interferon ⁇ -treated U937 cells for 3 hours at 14°C.
- a 500 fold excess of Miles gamma globulin was used to determine nonspecific binding.
- Specific binding is plotted as a percentage of the total number of counts.
- the fold excess of cold ligand is indicated on the x-axis and the % of specific binding is indicated on the y-axis.
- Figure 6 is a bar graph showing the binding of C1 q to antigen-antibody coated plates.
- C1 q binding was detected by a sandwich ELISA with goat anti- human C1 q antibody and swine anti-goat alkaline phosphatase-conjugated secondary antibody. The absorbance at 410 nm is shown on the y-axis.
- One embodiment of the present invention is a method for the production of a bispecific, tetravalent antibody by the steps of: producing a DNA segment encoding a single chain antibody (SCAB) consisting of fused DNA segments encoding variable heavy and light (V H and V L ) immunoglobulin chains; ligating the SCAB DNA segment to a DNA segment encoding an immunoglobulin G (IgG) constant region; constructing an expression vector containing the SCAB-constant region ligation fused to a DNA segment encoding a V H region having a different specificity; and cotransfecting and expressing the vector and a vector containing a DNA segment encoding the V L region of the same specificity as the second V H region into cells.
- SCAB single chain antibody
- V H and V L variable heavy and light
- IgG immunoglobulin G
- the SCAB has the anti-dansyl V H and V L regions, is produced by PCR overlap extension and the V H -V L fusion is through a plurality of gly gly gly gly ser linkers.
- the IgG constant region is human and the expression vector is eukaryotic.
- the eukaryotic expression vector is pAH4633.
- the V H and V L specificities are preferably anti- dextran and the cells are mammalian. Most preferably, these mammalian cells are murine SP2/0 cells.
- Still another embodiment of the present invention consists of an isolated recombinant, bispecific antibody.
- a further embodiment is an expression vector encoding the bispecific antibody consisting of: DNA segment I encoding the V H and V L regions joined by a flexible linker;
- DNA segment II encoding a human lgG3 constant region fused to DNA segment I;
- DNA segment III encoding a V H region with a different specificity from the V H region of DNA segment I.
- the present invention also embodies a transformed cell line continuously expressing the bispecific antibody.
- Yet another embodiment of the present invention is a method for targeting immune cells to tumor cells by the steps of: contacting the immune cells with a recombinant tetravalent antibody
- Sr ⁇ STrruTE SHEET (RULE 6) having affinity for an antigen expressed on the immune cell surface on a first end of the antibody and affinity for a tumor cell surface antigen on a second end of the antibody; and administering the immune cell-antibody complex to tumor cells.
- Another aspect of the present invention includes activating the immune cells with a cytokine prior to the formation of an immune cell-antibody complex and injection into a mammal.
- a further aspect of the present invention includes directly injecting the aforementioned recombinant tetravalent antibody in vivo wherein the antibody is not complexed to an immune cell prior to injection.
- the immune cells are either cytotoxic T-cells or lymphokine activated killer cells administered in vitro and the cytokine is either IL-1 , IL-2, IL-6, interferon a or interferon y. Most preferably, the cells are administered in vivo.
- An even further embodiment of the present invention is a method for targeting toxins or chemotherapeutic agents to tumor cells by the steps of: contacting the agent with a recombinant tetravalent antibody having anti-toxin specificity at a first end of the antibody and affinity for a tumor cell antigen at a second end of the antibody; and administering the toxin-antibody complex to tumor cells.
- the toxin is either ricin, adriamycin, daunomycin, vindesine, doxorubicin or taxol and the tumor cells are in vitro. Most preferably, the tumor cells are in vivo.
- another embodiment of the present invention is a method of identi ⁇ fying antigens present in a biological sample or expressed on the cell surface by the steps of: isolating a biological sample of interest; contacting the biological sample with an isolated bispecific antibody having affinity for an antigen of interest at one of its ends and affinity for a adiolabeled compound, dye or enzyme able to catalyze a colorimetric reaction at its other end; and detecting the binding of the antibody to the antigen of interest.
- Stt ⁇ STITUTE SHEET (RULE 26 having a different specificity. This gene fusion is expressed by transfection resulting in a tetravalent antibody having dual specificity.
- the advantages of this approach over the prior art include production of a homogeneous antibody population, all molecules having two sites which bind one antigen and two sites which bind a different antigen. Additionally, since the constant region of the antibody is preserved, the molecule can bind to F c receptors on monocytic cells. Finally, the antibody may be more effective at inducing target cell lysis due to the presence of twice as many binding sites for each antigen, thus increasing its avidity for both target and effector cells.
- Bispecific, tetravalent antibodies have the ability to bind a total of four antigens of two different types (two at each end).
- the antibodies are produced by combining a DNA sequence encoding a SCAB with a DNA sequence encoding the heavy chain region of a different antibody. Normally these sequences are combined such that the constant region of the heavy chain antibody is linked to the variable region of the SCAB through a short flexible linker region.
- the nucleotide sequences encoding the heavy chain and the SCAB are advantageously inserted into an expression vector and transfected into a cell line capable of expressing the protein product. Cells transfected with the aforementioned construct are cotransfected with a separate vector encoding the light chain corresponding to the aforementioned heavy chain. In this manner, the transfected cells produce a single protein species comprising the heavy chain linked to the SCAB and a second protein comprising the light chain. These proteins assemble to produce functional antibodies and are secreted.
- This method imparts predictability to the process of producing bispecific antibodies.
- a SCAB with a known specificity and a heavy chain from a second antibody, also having a known specificity, can be combined to predictably produce a tetravalent, bispecific antibody. This predictability is very advantageous in view of the prior art methods of producing bispecific antibodies.
- tetravalent, tetraspecific antibody able to bind four antigens, each having a different specificity
- a tetravalent, trispecific antibody able to bind one antigen at one of its ends and two antigens at its other end
- a tetravalent monospecific antibody able to bind four antigens of a particular type.
- a tetravalent, monospecific antibody will advantageously increase the avidity of antigen binding and will be especially useful for immunodiagnostics.
- monospecific antibody will advantageously increase the avidity of antigen binding and will be especially useful for immunodiagnostics.
- catalytic antibodies can be generated by the method of the present invention and targeted to an antigen such as a tumor cell marker.
- the other end of the molecule comprises an antibody having catalytic activity.
- the catalytic antibody may act as a protease which, once inside the target cell, will hydrolyze essential proteins resulting in cell death.
- the two specificities of the antibody described in the present invention are directed towards dansyl and dextran, these specificities are only illustrative. Using this technology, one of ordinary skill in the art will be able to engineer antibodies having a wide variety of specificities.
- the recombinantly- expressed, isolated antibodies will be particularly useful for targeting activated immune cells to tumor cells by simultaneously binding antigens on the tumor cells and effector cells, thus bringing the cells in close proximity and resulting in tumor cell lysis.
- the antibody can also be engineered to bind a toxin or chemotherapeutic agent at one of its ends and a tumor cell antigen at its other end, also resulting in tumor cell lysis by specifically delivering the toxin to the tumor cell. Due to the immunological specificity of the delivery mechanism, normal cells will not be appreciably affected.
- the antibodies of the present invention will also be useful as immunodiagnostic agents in the detection of a number of pathological conditions including cancer, AIDS and bacterial infections.
- the antibody molecules can be engineered to have an affinity for tumor cell markers, HIV envelope glycoproteins such as gp1 20, bacterial membrane proteins or viral surface proteins such as influenza hemagglutinin at one end and an affinity for an enzyme able to catalyze a colorimetric reaction at the other end.
- HIV envelope glycoproteins such as gp1
- bacterial membrane proteins or viral surface proteins such as influenza hemagglutinin at one end
- an enzyme able to catalyze a colorimetric reaction at the other end.
- one means of expressing the recombinant antibody is by insertion into the eukaryotic expression vector pAH4633 and expression in murine cells, other eukaryotic expression vectors and eukaryotic cell types known by those of ordinary skill in the art are also within the scope of the present invention.
- IL-1 , IL-2, IL-6 or the interferons are also within the scope of the present invention as a means of targeting activated immune cells to tumor cells.
- toxins and chemotherapeutic agents other than those specifically mentioned can also be bound by the bispecific antibodies of the present invention.
- SUBSTITUTE SHEET (RULE Of It is also envisioned that in the use of the antibody of the present invention as an immunodiagnostic agent, a number of detection systems could be used including, but not limited to, colorimetric labels, radiolabels and dyes.
- an anti-dansyl single chain antibody was constructed as described in the following example.
- Example 1 Construction of an anti-dansyl single chain antibody
- SCAB anti-dansyl single chain antibody
- a flexible linker region consisting of three gly gly gly gly ser repeats was used to connect the C-terminus of the heavy chain variable region (V H ) and the N-terminus of the light chain variable region (V L ) in order to maximize flexibility while minimizing steric hindrance during protein folding (Huston et al., (1 988) Proc. Natl. Acad. Sci. USA, 85: 5879-5883).
- the 3' primer for V H (B) (SEQ ID NO: 1 ) and the 5' primer for V L (C) (SEQ ID NO: 2) were designed to have a complementary region in the linker portion.
- the V H and V L regions were independently amplified, followed by a second PCR reaction in which these products were used as templates.
- the complementary sequences in the linker hybridized, joining the V regions, and the primers A (SEQ ID NO: 3) and D (SEQ ID NO: 4) were then used to amplify the SCAB ( Figure 1 ).
- the 5' primer used to amplify V H was designed to eliminate a BamHI site present in amino acid 1 6 of framework 1 (FR1 ).
- PCR reactions were performed in a final volume of 100 //I in 10 mM Tris-HCI, pH 8.0, 1 .5 mM MgCI 2 , 50 mM KG, 100 / g bovine serum albumin and 2.5 units Taq polymerase for 25 cycles at 94°C for 1 min, 55°C for 1 min and 72°C for 1 min.
- the size of the PCR products was verified by agarose gel electrophoresis and staining with ethidium bromide.
- each first reaction was used as a template.
- the primers used were 5'A (SEQ ID NO: 3) and 3'D (SEQ ID NO: 4).
- the buffer and primer concentrations were the same as above.
- the PCR parameters were 1 min at 94°C, 1 .5 min at 60°C, 72°C for 2 min for 25 cycles and a 10 min extension at 72°C.
- Both the variable region fragments and the SCAB were cloned into plasmid Bluescript T-A (blunt ended by digestion with Eco RV and tailed with deoxythymidine triphosphate using terminal transferase (Holton and Graham, (1990) Nucl. Acids Res., 19: 1 1 56)).
- the plasmid was used to transform competent E. co// XL1 -blue cells (Stratagene).
- Example 2 Construction of the bispecific antibody expression vector
- the anti-dansyl SCAB contained a Pvull site at its 5' end and an EcoRI site at its 3' end. There were 14 additional base pairs upstream of the first codon of
- FR1 which provided a short flexible linker and allowed the cloning of the SCAB in frame with a human lgG3 constant region (in plasmid pSK3461 ) that had been mutagenized at its 3' end to introduce a Sspl site by adding TATT downstream of the last amino acid of C H 3.
- the resulting AATATT site when cut, provided two extra bases (GT) that maintained the reading frame in the linker region.
- pSK3461 also contained a linker region 3' of the Sspl site with an EcoRI site.
- a polyadenylation site was 3' of the EcoRI site. Cloning into the Sspl and EcoRI sites thus provided a constant region fusion containing a polyadenylation signal ( Figure 2).
- pAH3617 is a 14 kb eukaryotic expression vector which contains the anti- dextran V H chain, human lgG3 constant region, and SV40 promoter and enhancer 5' of the V H chain.
- both plasmids pSK4629 and pAH361 7 were cut with BamHI and Sail.
- the final expression vector, pAH4633 contained an SV40 promoter and enhancer, the anti- dextran V H region, the human lgG3 constant region joined to the anti-dansyl SCAB, a histidinol eukaryotic selectable marker and an ampicillin prokaryotic selectable marker.
- SCAB was joined to the CH 3 region of the heavy chain antibody, one of ordinary skill in the art will appreciate that the SCAB can also be joined to the heavy chain antibody at other positions including after CH,, after the hinge region and after CH 2 .
- Vectors are available which will facilitate these combinations and the resulting recombinant antibodies will also be bispecific.
- the light chain expression vector pAH3634 contained the anti-dextran V L region, the human kappa constant region and an SV40 promoter and enhancer. Prior to transfection, 10 ⁇ g of pAH4633 and pAH3634 DNA were linearized using BspCI (blunt cutter) which cuts within the ampicillin resistance gene. The nonproducing murine myeloma cell line SP2/0 was used as a recipient in independent transfections.
- the cells were washed in cold Iscove's Modified Dulbecco's Medium (IMDM; Gibco, Grand Island, NY) containing 10% fetal calf serum (FCS) and resuspended at 10 5 cells/ml in IMDM containing 10% FCS, 100 units/ml nystatin and 1 OO ⁇ g/ml gentamycin.
- IMDM Iscove's Modified Dulbecco's Medium
- FCS fetal calf serum
- FCS fetal calf serum
- the cells were plated in 96 well microtiter plates at 100 /l/well. After two days 10O /I of selection medium containing 5 mM histidinol was added to each well.
- clones Positive clones were detected by enzyme-linked immunosorbent assay (ELISA) of the cell culture supernatants using 96 well dansyl-BSA-coated microtiter plates. The highest producing clones were expanded to 5 and 25 ml petri dishes. The transfectant in SP2/0 was named TAAM and exhibited dansyl binding.
- ELISA enzyme-linked immunosorbent assay
- Example 4 Analysis of antibodies in cell culture supernatants Transfectants were metabolically labeled with 35 S methionine overnight, centrifuged and the supernatant analyzed for the presence of secreted Ig. To analyze intracellular Ig, cytoplasmic extracts were prepared by lysing the cells with
- NP-40 0.5% NP-40 in isotonic buffer. Cytoplasmic and secreted antibodies were immunoprecipitated with rabbit anti-human constant region antiserum followed by addition of Staphylococcus aureus protein A for 1 5 min at 4°C. The samples were layered over a 30% sucrose pad containing NDET (10 mM Tris-HG, pH 7.4, 1 % NP-40, 0.4% sodium deoxycholate, 66 mM EDTA), centrifuged for 5 min, and the supernatant discarded. The pellet was washed once with water, resuspended in sample buffer (25 mM Tris-HG, pH 6.8, 2% SDS, 10% glycerol, 0.008% bromphenol blue) and boiled for 2 min.
- sample buffer 25 mM Tris-HG, pH 6.8, 2% SDS, 10% glycerol, 0.008% bromphenol blue
- transfectants To analyze the size of the protein synthesized by the transfectants, immunoprecipitates were analyzed on 12% Tris- glycine SDS gels after reduction with 2-mercaptoethanol. The assembly pattems and polymerization state of the Igs were determined by fractionating the immunoprecipitates on 5% phosphate gels under nonreducing conditions. The transfectants produced a secreted Ig of 226 kDa, the size expected for the construct. To determine whether the secreted bispecific antibodies were N-linked glycosylated, transfectants were metabolically labelled as described above but in the presence of tunicamycin, an inhibitor of N-linked glycosylation. The labeled antibody was immunoprecipitated and analyzed by SDS polyacrylamide gel electrophoresis.
- mice 4-6 weeks old were administered 10 mg/ml potassium iodide in water for 6 days prior to the experiment in order to saturate the thyroid with cold iodine to reduce any background counts.
- [ 125 l] labeled protein (1 x 10 6 cpm of TAAM, TPO, and BSA) in 250 I sterile PBS was injected intraperitoneally into mice in triplicate. Whole body counts were taken at various time points for a total of
- Example 7 F practice receptor binding assay Human U937 monocytic cells expressing the high affinity F c yR ⁇ receptor were grown in RPMI containing 10% FCS and stimulated with 100 units/ml human interferon for 2-3 days prior to the assay. Cells were harvested by centrifugation at 1 ,000 rpm for 5 min, washed in cold PBS and counted using a hemocytometer. The cells were resuspended at 1 x 10 7 cells/ml in serum-free DMEM and incubated fpr 2 hours at 37°C.
- Eppendorf tubes were prepared which contained a constant amount of [ 125 l] labeled recombinant antibody (approximately 20 ng; 1 x 10 5 cpm) in 50 ml binding buffer (0.1 M HEPES, pH 7.4-7.7, 0.1 2 M NaCl, 5 mM KG, 1 .2 mM MgS0 4 , 1 5 mM acetic acid, 10 mM glucose, 1 % BSA).
- 50 ml binding buffer 0.1 M HEPES, pH 7.4-7.7, 0.1 2 M NaCl, 5 mM KG, 1 .2 mM MgS0 4 , 1 5 mM acetic acid, 10 mM glucose, 1 % BSA.
- Example 9 Use of tetravalent antibody conjugates to Ivse tumor cells
- Recombinant bispecific monoclonal antibodies having both anti-CD3 or anti- IL-2 receptor (found on activated T-cells) and anti-tumor cell antigen affinities are produced using the method described in Examples 1 -3.
- Other T cell surface antigens are also within the scope of the present invention.
- a variety of tumor cell antigens can be targeted including, but not limited to, the 145 kDa cell surface glycoprotein expressed on human gliomas and small lung carcinomas, the carcinoembryonic antigen expressed on a wide range of tumor cells and the Le y antigen expressed on breast, lung and colon carcinoma.
- PBMC Peripheral blood mononuclear cells
- PBMC Peripheral blood mononuclear cells
- the cells are then incubated in culture medium in the presence or absence of 100 units/ml recombinant human IL-2 for 3 days at 37°C.
- Control cells receive no lL-2.
- Target tumor cells are labeled with 51 Cr and plated in 96 well microtiter plates and about 0.1 -about 100 ⁇ g recombinant antibody is added to each well for about 30- about 60 min.
- Activated T-cells are then added for about 4 hours. Cytolysis is assessed by gamma counting of the cell supernatant after centrifugation.
- the use of other activating cytokines including but not limited to, IL-1 , IL-6, and the interferons is also contemplated.
- Tetravalent, bispecific antibodies are complexed with T cells.
- these immune cells may be activated in vitro prior to complex formation.
- the immune cell-antibody complex is then injected into a mammal, preferably a human, in an amount sufficient to promote tumor cell lysis and tumor regression.
- the tetravalent antibody is injected by itself whereupon it promotes the union of immune cells and tumor cells in vivo without the need for prior immune cell-antibody complex formation.
- the amount of immune cell-antibody complex or of antibody alone administered will depend on the type and size of the carcinoma, the extent of metastasis, the activation state of the immune cell and the affinity of the antibody for the tumor cell antigen.
- NK natural killer
- LAK lymphokine-activated killer
- a similar experiment can be performed using an antibody specific for the same aforementioned anti-T cell antigens and for a toxin or chemotherapeutic agent such as ricin or vindesine, respectively.
- the bispecific, tetravalent antibody is necessarily complexed to the toxin or chemotherapeutic agent in vitro prior to injection in vivo.
- the bispecific antibody can then deliver such an agent to tumor cells resulting in tumor cell lysis and tumor regression.
- the tetravalency of the recombinant antibody provides a greater binding capacity than bivalent recombinant antibodies, since each end of the molecule can bind two antigens thus delivering twice as much chemotherapeutic agent or toxin to the target cell as would a similar bivalent antibody. Thus, the amount of antibody to be administered could be reduced without reducing its efficacy. In addition, since the antigen combining sites are located on opposite ends of the molecule, this provides greater binding flexibility thus allowing the antibody to bridge greater distances between targets.
- the antibody of the present invention can also be used in immunodiagnostics as described below.
- Example 10 Use of the tetravalent antibody in immunodiagnostics
- a bispecific tetravalent antibody is produced by the method described in the examples above having a specificity against both a tumor cell antigen of interest and either a radiolabeled compound, a dye or a protein capable of catalyzing a colorimetric reaction.
- the labeled antibody can be used to stain cell or tissue sections to determine the presence of a tumor cell antigen.
- certain proteins are released from tumors into the blood, such as prostatic acid phosphatase from prostate cancer cells, this antibody will be useful in detecting these antigens by enzyme-linked immunosorbent assay (ELISA) or radioimmunoassay, a technique well known in the art.
- ELISA enzyme-linked immunosorbent assay
- radioimmunoassay a technique well known in the art.
- the antibody can also be used to detect viruses and bacteria in body fluids. While particular embodiments of the invention have been described in detail, it will be apparent to those skilled in the art that these embodiments are exemplary, rather than limiting, and the true scope of the invention is that defined in the following claims.
- MOLECULE TYPE CDNA
- HYPOTHETICAL NO
- ANTI-SENSE NO
- MOLECULE TYPE cDNA
- HYPOTHETICAL NO
- ANTI-SENSE NO
- MOLECULE TYPE cDNA
- HYPOTHETICAL NO
- ANTI-SENSE NO
- MOLECULE TYPE cDNA
- HYPOTHETICAL NO
- ANTI-SENSE NO
- MOLECULE TYPE cDNA
- HYPOTHETICAL NO
- ANTI-SENSE NO
Abstract
The invention relates to a method for the production of recombinant bispecific tetravalent antibodies. These antibodies are useful in targeting toxins and activated T cells to tumor cells as well as in immunodiagnostics. These antibodies are constructed by fusing a DNA segment encoding a single chain antibody with a DNA segment encoding an IgG constant region. This fusion is then ligated to a DNA segment encoding a heavy chain variable region with different specificity. Cells are cotransfected with this construct and a vector encoding a light chain variable region having the same specificity as the heavy chain variable region.
Description
GENETICALLY ENGINEERED BISPECIFIC TETRAVALENT ANTIBODIES
GOVERNMENT SUPPORT This research was supported by United States Public Health Service grants CA1 6858 and AI29470. The United States government may have certain rights in this invention in the United States.
FIELD OF THE INVENTION
This invention relates to the production of bispecific, tetravalent antibodies using recombinant DNA methods. The antibody protein is produced at the DNA level and expressed by transfection. The resulting antibody has two different specificities, one at the N-terminus and one at the C-terminus. This invention may have both therapeutic and immunodiagnostic applications.
BACKGROUND OF THE INVENTION
The development of monoclonal antibody technology has resulted in an explosion of research into the diagnosis and treatment of cancer and other disorders of the immune system. However, the use of murine monoclonal antibodies in humans has had limited success, mainly due to development of a human anti-mouse antibody response accompanying the long-term use of these molecules (Schroff et al., (1 985) Cancer Res., 45: 879; Steinitz et al., (1 988) J.
Immunol., 141 : 3515). To make murine monoclonal antibodies less antigenic to humans, investigators have engineered antibodies containing human framework sequences in the majority of the molecule but murine sequences in the complementarity determining regions (CDRs) of the heavy and light chain hypervariable regions or antibodies with murine variable regions and human constant regions (Boulianne et al., (1984) Nature, 312: 643-646; Neuberger et al., (1 985) Nature, 314: 268-270;
Morrison, (1 992) Annu. Rev. Biochem., 10: 239-265). Another approach to producing more effective monoclonal antibodies is the conjugation of chemotherapeutic drugs and other toxins in order to effectively target these molecules to cancer cells (Krolick et al., (1992) J. Exp. Med., 155: 1797; Vitetta et al., (1 983) Science, 219: 644; Nolan et al., (1992) Intl. J. Clin. Lab. Res., 22:
21 ).
Another potential means of producing more effective antibodies is the development of bispecific molecules capable of simultaneously binding two different antigens (Wong and Colvin, (1 987) J. Immunol., 139: 1 369). These antigens may be, for example, a tumor cell antigen and an effector cell such as an
activated T cell or functional agent such as a cytotoxin (Flavell et al., (1 991 ) British J. Cancer, 64: 274; Runge et al., (1990) Bioconjugate Chem., 1 : 274). Such tumor cell antigens include carcinoembryonic antigen, a widely-expressed tumor cell marker and Lev antigen expressed on breast, lung and colon carcinomas. This provides an effective means to facilitate targeting of these cells and toxins to transformed cells. This method has been used to increase cytotoxicity of activated T cells toward human glioma cells (Nitta et al., (1 990) J. Neurosurg., 72: 476-481 ; Nishimura et al., (1992) J. Immunol., 148: 285-291 ) and to target the toxins ricin and vindesine to tumor cells (Embleton et al., (1 991 ) British J. Cancer, 63: 670- 674; Corvalan and Smith, (1 987) Cancer Immunol. Immunother., 24: 127-1 32).
Finally, catalytic antibodies have also been described which may act as highly selective catalysts in biology, chemistry and medicine (Shokat and Schultz, (1 990) Annu. Rev. Immunol. 8: 335-363).
Bispecific antibodies have been produced using a variety of methods. Univalent fragments of pepsin-treated antibodies of different specificities or of complete antibodies have been chemically linked to produce bispecific antibodies (Raso and Griffin, (1981 ) Cancer Res., 41 : 2073; Glennie et al., (1987) J. Immunol., 139: 2367; Glennie et al., (1988) J. Immunol. 141 : 3662-3670). In addition, fusion of two hybridoma cells yields a hybrid hybridoma called a quadroma which produces some mixed molecules having the specificities of each hybridoma
(Reading, (1983) in Hybridomas and Cellular Immortality, B. H. Tom and J. P. Allison, eds., p.235, Plenum Press, New York; Milstein and Cuello, (1 984) Immunol. Today, 5: 299; Kontsekova et al., (1992) Hybridoma, 1 1 : 461 ; Lloyd et al., (1991 ) J. Nat. Med. Assoc, 83: 901 ). Genetically engineered single chain antibodies against molecules including bovine growth hormone, digoxin and fluorescein have also been produced (Bird et al., (1 988) Science, 242: 423-426; Huston et al., (1 988) Proc. Natl. Acad. Sci. USA, 85: 5879-5883; Bedzyk et al., (1 990) J. Biol. Chem., 265, 1861 5-18620).
Unfortunately, all of the aforementioned approaches have certain disadvantages and limitations. Chemical modification of antibodies is tedious and can lead to side reactions which damage the antigen combining site. Quadroma production has proven inefficient due to the difficulty in separating the bispecific antibodies from the diverse population secreted by the original two hybridomas. Finally, single chain antibodies without constant regions also lack Fc-mediated effector functions such as Fc receptor binding and complement fixation.
BRIEF DESCRIPTION OF THE FIGURES Figure 1 illustrates the primers and PCR reactions used to generate the anti- dansyl single chain antibody. Primers A and B were used to amplify VH and to incorporate restriction sites and linkers. Primers C and D were used to amplify VL. In a second round of PCR the products of the previous reaction were used as templates. Primers A and D were used to amplify and join the VH and VL to produce the SCAB. The number of nucleotides in the primer and their origin are indicated below the arrows. X = extra nucleotides.
Figure 2 illustrates the construction of the pAH4633 expression vector expressing the heavy chain of the bispecific antibody. The PCR generated single chain antibody was subcloned into pSK3461 , an intermediate vector containing a human lgG3 constant region. The BamH1 -Sal1 fragment containing the constant region of the SCAB from pSK4629 replaced the same fragment from pAH3617, an anti-dextran VH expression vector to generate pAH4633. Figure 3 is a schematic representation of the expected structure of the bispecific antibody. An anti-dansyl SCAB was fused to the 3' end of an anti- dextran lgG3 chimeric antibody. The arrows indicate the antigen combining sites. Figure 4 indicates a half-life determination of the bispecific antibody. 1 x 106 counts of [125l] labeled antibody were injected intraperitoneally into mice in triplicate and whole body counts were measured. The time, in hours, is indicated on the x-axis and the % of cpm remaining is indicated on the y-axis. TAAM = SP2/0 transfectant; TPO = lgG3 chimeric wild type antibody. The half-life of each antibody, in days, is indicated.
Figure 5 illustrates a high affinity Fc receptor binding assay. 125l labeled antibodies were incubated in the presence of varying amounts of excess cold ligand with 2 x 106 interferon ^-treated U937 cells for 3 hours at 14°C. A 500 fold excess of Miles gamma globulin was used to determine nonspecific binding. Specific binding is plotted as a percentage of the total number of counts. The fold excess of cold ligand is indicated on the x-axis and the % of specific binding is indicated on the y-axis.
Figure 6 is a bar graph showing the binding of C1 q to antigen-antibody coated plates. C1 q binding was detected by a sandwich ELISA with goat anti- human C1 q antibody and swine anti-goat alkaline phosphatase-conjugated secondary antibody. The absorbance at 410 nm is shown on the y-axis. SUMMARY OF THE INVENTION
One embodiment of the present invention is a method for the production of a bispecific, tetravalent antibody by the steps of: producing a DNA segment encoding a single chain antibody (SCAB) consisting of fused DNA segments encoding variable heavy and light (VH and VL) immunoglobulin chains; ligating the SCAB DNA segment to a DNA segment encoding an immunoglobulin G (IgG) constant region; constructing an expression vector containing the SCAB-constant region ligation fused to a DNA segment encoding a VH region having a different specificity; and cotransfecting and expressing the vector and a vector containing a DNA segment encoding the VL region of the same specificity as the second VH region into cells.
Preferably, in this method, the SCAB has the anti-dansyl VH and VL regions, is produced by PCR overlap extension and the VH-VL fusion is through a plurality of gly gly gly gly ser linkers. Advantageously, the IgG constant region is human and the expression vector is eukaryotic. Most preferably, the eukaryotic expression vector is pAH4633. In addition, the VH and VL specificities are preferably anti- dextran and the cells are mammalian. Most preferably, these mammalian cells are murine SP2/0 cells.
Still another embodiment of the present invention consists of an isolated recombinant, bispecific antibody.
A further embodiment is an expression vector encoding the bispecific antibody consisting of: DNA segment I encoding the VH and VL regions joined by a flexible linker;
DNA segment II encoding a human lgG3 constant region fused to DNA segment I; and
DNA segment III encoding a VH region with a different specificity from the VH region of DNA segment I.
The present invention also embodies a transformed cell line continuously expressing the bispecific antibody.
Yet another embodiment of the present invention is a method for targeting immune cells to tumor cells by the steps of: contacting the immune cells with a recombinant tetravalent antibody
SrøSTrruTE SHEET (RULE 6)
having affinity for an antigen expressed on the immune cell surface on a first end of the antibody and affinity for a tumor cell surface antigen on a second end of the antibody; and administering the immune cell-antibody complex to tumor cells. Another aspect of the present invention includes activating the immune cells with a cytokine prior to the formation of an immune cell-antibody complex and injection into a mammal.
A further aspect of the present invention includes directly injecting the aforementioned recombinant tetravalent antibody in vivo wherein the antibody is not complexed to an immune cell prior to injection.
Preferably, the immune cells are either cytotoxic T-cells or lymphokine activated killer cells administered in vitro and the cytokine is either IL-1 , IL-2, IL-6, interferon a or interferon y. Most preferably, the cells are administered in vivo. An even further embodiment of the present invention is a method for targeting toxins or chemotherapeutic agents to tumor cells by the steps of: contacting the agent with a recombinant tetravalent antibody having anti-toxin specificity at a first end of the antibody and affinity for a tumor cell antigen at a second end of the antibody; and administering the toxin-antibody complex to tumor cells. Preferably, the toxin is either ricin, adriamycin, daunomycin, vindesine, doxorubicin or taxol and the tumor cells are in vitro. Most preferably, the tumor cells are in vivo.
Finally, another embodiment of the present invention is a method of identi¬ fying antigens present in a biological sample or expressed on the cell surface by the steps of: isolating a biological sample of interest; contacting the biological sample with an isolated bispecific antibody having affinity for an antigen of interest at one of its ends and affinity for a adiolabeled compound, dye or enzyme able to catalyze a colorimetric reaction at its other end; and detecting the binding of the antibody to the antigen of interest.
DETAILED DESCRIPTION OF THE INVENTION
We describe a new method of producing bispecific, tetravalent antibodies using recombinant DNA technology. Our approach is the production of a single chain antibody (SCAB; Chaudary et al., (1 990) Proc. Natl. Acad. Sci. USA, 87: 1066; Ayala et al., (1992) BioTech, 13: 790) and its fusion to a complete antibody
SttøSTITUTE SHEET (RULE 26
having a different specificity. This gene fusion is expressed by transfection resulting in a tetravalent antibody having dual specificity. The advantages of this approach over the prior art include production of a homogeneous antibody population, all molecules having two sites which bind one antigen and two sites which bind a different antigen. Additionally, since the constant region of the antibody is preserved, the molecule can bind to Fc receptors on monocytic cells. Finally, the antibody may be more effective at inducing target cell lysis due to the presence of twice as many binding sites for each antigen, thus increasing its avidity for both target and effector cells. Bispecific, tetravalent antibodies have the ability to bind a total of four antigens of two different types (two at each end). The antibodies are produced by combining a DNA sequence encoding a SCAB with a DNA sequence encoding the heavy chain region of a different antibody. Normally these sequences are combined such that the constant region of the heavy chain antibody is linked to the variable region of the SCAB through a short flexible linker region. The nucleotide sequences encoding the heavy chain and the SCAB are advantageously inserted into an expression vector and transfected into a cell line capable of expressing the protein product. Cells transfected with the aforementioned construct are cotransfected with a separate vector encoding the light chain corresponding to the aforementioned heavy chain. In this manner, the transfected cells produce a single protein species comprising the heavy chain linked to the SCAB and a second protein comprising the light chain. These proteins assemble to produce functional antibodies and are secreted.
This method imparts predictability to the process of producing bispecific antibodies. A SCAB with a known specificity and a heavy chain from a second antibody, also having a known specificity, can be combined to predictably produce a tetravalent, bispecific antibody. This predictability is very advantageous in view of the prior art methods of producing bispecific antibodies.
One of ordinary skill will also appreciate the possibility of engineering, using similar methods, a tetravalent, tetraspecific antibody able to bind four antigens, each having a different specificity, a tetravalent, trispecific antibody able to bind one antigen at one of its ends and two antigens at its other end and a tetravalent monospecific antibody able to bind four antigens of a particular type. A tetravalent, monospecific antibody will advantageously increase the avidity of antigen binding and will be especially useful for immunodiagnostics. In addition,
SUBSΠTIΠΈ SHEET (RULE W.
catalytic antibodies can be generated by the method of the present invention and targeted to an antigen such as a tumor cell marker. The other end of the molecule comprises an antibody having catalytic activity. For example, the catalytic antibody may act as a protease which, once inside the target cell, will hydrolyze essential proteins resulting in cell death.
Although the two specificities of the antibody described in the present invention are directed towards dansyl and dextran, these specificities are only illustrative. Using this technology, one of ordinary skill in the art will be able to engineer antibodies having a wide variety of specificities. The recombinantly- expressed, isolated antibodies will be particularly useful for targeting activated immune cells to tumor cells by simultaneously binding antigens on the tumor cells and effector cells, thus bringing the cells in close proximity and resulting in tumor cell lysis. In a similar fashion, the antibody can also be engineered to bind a toxin or chemotherapeutic agent at one of its ends and a tumor cell antigen at its other end, also resulting in tumor cell lysis by specifically delivering the toxin to the tumor cell. Due to the immunological specificity of the delivery mechanism, normal cells will not be appreciably affected.
The antibodies of the present invention will also be useful as immunodiagnostic agents in the detection of a number of pathological conditions including cancer, AIDS and bacterial infections. The antibody molecules can be engineered to have an affinity for tumor cell markers, HIV envelope glycoproteins such as gp1 20, bacterial membrane proteins or viral surface proteins such as influenza hemagglutinin at one end and an affinity for an enzyme able to catalyze a colorimetric reaction at the other end. Although one means of expressing the recombinant antibody is by insertion into the eukaryotic expression vector pAH4633 and expression in murine cells, other eukaryotic expression vectors and eukaryotic cell types known by those of ordinary skill in the art are also within the scope of the present invention. It is also envisioned that one of ordinary skill will be able to activate immune cells with other molecules in addition to IL-1 , IL-2, IL-6 or the interferons. These other activating molecules, as well as other types of activated immune cells, are also within the scope of the present invention as a means of targeting activated immune cells to tumor cells. In addition, it will be appreciated that toxins and chemotherapeutic agents other than those specifically mentioned can also be bound by the bispecific antibodies of the present invention.
SUBSTITUTE SHEET (RULE Of
It is also envisioned that in the use of the antibody of the present invention as an immunodiagnostic agent, a number of detection systems could be used including, but not limited to, colorimetric labels, radiolabels and dyes.
As a first step in engineering a recombinant bispecific tetravalent antibody, an anti-dansyl single chain antibody was constructed as described in the following example.
Example 1 Construction of an anti-dansyl single chain antibody An anti-dansyl single chain antibody (SCAB) was produced using PCR to join two variable regions by overlap extension (Ho et al., (1989) Gene, 77: 51 ). A flexible linker region consisting of three gly gly gly gly ser repeats was used to connect the C-terminus of the heavy chain variable region (VH) and the N-terminus of the light chain variable region (VL) in order to maximize flexibility while minimizing steric hindrance during protein folding (Huston et al., (1 988) Proc. Natl. Acad. Sci. USA, 85: 5879-5883).
For the PCR reaction, the 3' primer for VH (B) (SEQ ID NO: 1 ) and the 5' primer for VL (C) (SEQ ID NO: 2) were designed to have a complementary region in the linker portion. The VH and VL regions were independently amplified, followed by a second PCR reaction in which these products were used as templates. The complementary sequences in the linker hybridized, joining the V regions, and the primers A (SEQ ID NO: 3) and D (SEQ ID NO: 4) were then used to amplify the SCAB (Figure 1 ). The 5' primer used to amplify VH was designed to eliminate a BamHI site present in amino acid 1 6 of framework 1 (FR1 ). With this approach, amplification and mutagenesis were reduced to a single step. Briefly, 50 ng of plasmid containing a cloned anti-dansyl VH or VL was used as a template for PCR. The primers used are shown in Table 1 . PCR reactions were performed in a final volume of 100 //I in 10 mM Tris-HCI, pH 8.0, 1 .5 mM MgCI2, 50 mM KG, 100 / g bovine serum albumin and 2.5 units Taq polymerase for 25 cycles at 94°C for 1 min, 55°C for 1 min and 72°C for 1 min. The size of the PCR products was verified by agarose gel electrophoresis and staining with ethidium bromide.
In the second PCR reaction, 5 μ\ of each first reaction was used as a template. The primers used were 5'A (SEQ ID NO: 3) and 3'D (SEQ ID NO: 4).
The buffer and primer concentrations were the same as above. The PCR parameters were 1 min at 94°C, 1 .5 min at 60°C, 72°C for 2 min for 25 cycles and
a 10 min extension at 72°C. Both the variable region fragments and the SCAB were cloned into plasmid Bluescript T-A (blunt ended by digestion with Eco RV and tailed with deoxythymidine triphosphate using terminal transferase (Holton and Graham, (1990) Nucl. Acids Res., 19: 1 1 56)). The plasmid was used to transform competent E. co// XL1 -blue cells (Stratagene). White colonies containing inserts were picked, miniprep DNA was analyzed, and inserts were sequenced using Sequenase (United States Biochemical) according to the manufacturer's instructions. Several independent clones from different PCR reactions were sequenced in both directions (Figure 2; SEQ ID NO: 5). The sequences were analyzed for PCR-induced mutations, verification of correct joining of the variable regions and for the presence of restriction sites. Large preparations of the correct clones were prepared using the maxi DNA prep kit (QIAGEN). Although the SCAB was constructed in the order VH-linker-VL, the reverse construct VL-linker-VH is also within the scope of the present invention. The SCAB was then fused to a human lgG3 constant region to produce a recombinant bispecific antibody as described in the following example.
Example 2 Construction of the bispecific antibody expression vector The anti-dansyl SCAB contained a Pvull site at its 5' end and an EcoRI site at its 3' end. There were 14 additional base pairs upstream of the first codon of
FR1 which provided a short flexible linker and allowed the cloning of the SCAB in frame with a human lgG3 constant region (in plasmid pSK3461 ) that had been mutagenized at its 3' end to introduce a Sspl site by adding TATT downstream of the last amino acid of CH3. The resulting AATATT site, when cut, provided two extra bases (GT) that maintained the reading frame in the linker region. pSK3461 also contained a linker region 3' of the Sspl site with an EcoRI site. A polyadenylation site was 3' of the EcoRI site. Cloning into the Sspl and EcoRI sites thus provided a constant region fusion containing a polyadenylation signal (Figure 2). To clone the SCAB into the above vector, a complete EcoRI digestion and a partial Sspl digestion were performed. The 6.6 kb vector was ligated to the 770 base pair SCAB and the plasmid was used to transform competent E. coli HB101 cells. Positive clones were screened by restriction analysis of miniprep DNA. The final 7.4 kb construct was called pBSK4629 (Figure 2). pAH3617 is a 14 kb eukaryotic expression vector which contains the anti-
dextran VH chain, human lgG3 constant region, and SV40 promoter and enhancer 5' of the VH chain. To replace the constant region of this vector with the constant region containing the downstream anti-dansyl SCAB, both plasmids pSK4629 and pAH361 7 were cut with BamHI and Sail. The 4.4 kb Sall-BamHI piece from pBSK4632, including the human lgG3 constant region, and the anti-dansyl SCAB containing a stop codon and a polyadenylation signal, were ligated to the expression vector thus replacing the original constant region (Figure 2). The final expression vector, pAH4633, contained an SV40 promoter and enhancer, the anti- dextran VH region, the human lgG3 constant region joined to the anti-dansyl SCAB, a histidinol eukaryotic selectable marker and an ampicillin prokaryotic selectable marker.
Although the SCAB was joined to the CH3 region of the heavy chain antibody, one of ordinary skill in the art will appreciate that the SCAB can also be joined to the heavy chain antibody at other positions including after CH,, after the hinge region and after CH2. Vectors are available which will facilitate these combinations and the resulting recombinant antibodies will also be bispecific.
To produce a complete bispecific tetravalent antibody (Figure 3), it was necessary to cotransf ect both the heavy and light chain Ig vectors as described in the following example: Example 3
Transfection and Selection The light chain expression vector pAH3634 contained the anti-dextran VL region, the human kappa constant region and an SV40 promoter and enhancer. Prior to transfection, 10 μg of pAH4633 and pAH3634 DNA were linearized using BspCI (blunt cutter) which cuts within the ampicillin resistance gene. The nonproducing murine myeloma cell line SP2/0 was used as a recipient in independent transfections.
For electroporation, 2 x 106 cells in log phase were washed twice with cold phosphate buffered saline (PBS) and resuspended in 0.9 ml of the same buffer containing the linearized vector. The cells were incubated in a 0.4 cm gap electroporation cuvette (Bio-Rad Laboratories) for 10 min on ice. Using a Gene Pulser (Bio-Rad), an electrical pulse of 200 volts and 900 microfarads was delivered and the cuvette was incubated as above. The cells were washed in cold Iscove's Modified Dulbecco's Medium (IMDM; Gibco, Grand Island, NY) containing 10% fetal calf serum (FCS) and resuspended at 105 cells/ml in IMDM containing 10%
FCS, 100 units/ml nystatin and 1 OOμg/ml gentamycin. The cells were plated in 96 well microtiter plates at 100 /l/well. After two days 10O /I of selection medium containing 5 mM histidinol was added to each well.
Positive clones were detected by enzyme-linked immunosorbent assay (ELISA) of the cell culture supernatants using 96 well dansyl-BSA-coated microtiter plates. The highest producing clones were expanded to 5 and 25 ml petri dishes. The transfectant in SP2/0 was named TAAM and exhibited dansyl binding.
To determine whether the recombinant antibodies were correctly assembled and of the expected size, secreted antibodies were analyzed as described in the following example.
Example 4 Analysis of antibodies in cell culture supernatants Transfectants were metabolically labeled with 35S methionine overnight, centrifuged and the supernatant analyzed for the presence of secreted Ig. To analyze intracellular Ig, cytoplasmic extracts were prepared by lysing the cells with
0.5% NP-40 in isotonic buffer. Cytoplasmic and secreted antibodies were immunoprecipitated with rabbit anti-human constant region antiserum followed by addition of Staphylococcus aureus protein A for 1 5 min at 4°C. The samples were layered over a 30% sucrose pad containing NDET (10 mM Tris-HG, pH 7.4, 1 % NP-40, 0.4% sodium deoxycholate, 66 mM EDTA), centrifuged for 5 min, and the supernatant discarded. The pellet was washed once with water, resuspended in sample buffer (25 mM Tris-HG, pH 6.8, 2% SDS, 10% glycerol, 0.008% bromphenol blue) and boiled for 2 min. To analyze the size of the protein synthesized by the transfectants, immunoprecipitates were analyzed on 12% Tris- glycine SDS gels after reduction with 2-mercaptoethanol. The assembly pattems and polymerization state of the Igs were determined by fractionating the immunoprecipitates on 5% phosphate gels under nonreducing conditions. The transfectants produced a secreted Ig of 226 kDa, the size expected for the construct. To determine whether the secreted bispecific antibodies were N-linked glycosylated, transfectants were metabolically labelled as described above but in the presence of tunicamycin, an inhibitor of N-linked glycosylation. The labeled antibody was immunoprecipitated and analyzed by SDS polyacrylamide gel electrophoresis. The results indicated that the antibodies were N-linked glycosylated since when grown in the presence of 8 mg/ml tunicamycin the
transfectants secreted heavy chains with a decreased apparent molecular weight. To obtain larger amounts of antibody, a large scale protein purification was performed as described in the following example.
Example 5 Protein purification
After verifying the correct nature of the secreted antibodies, cells were expanded in tissue culture roller bottles containing 1 % alpha calf serum in IMDM. Four liters of cell culture supernatant from each clone were recovered and antibodies were purified on an affinity column containing a dansyl isomer coupled to Sepharose. The antibodies were eluted with a second dansyl isomer, which binds to the antibodies, thus competitively displacing them from the immobilized dansyl isomer, dialyzed against tris-saline and concentrated by vacuum. Purified antibodies were analyzed on 1 2% tris-glycine SDS gels for reduced samples or on 5 % phosphate gels for unreduced samples as described above. The purified protein was identical in molecular weight to the biosynthetically labeled protein described in Example 4.
Both the screening assay and the affinity purification demonstrated the affinity of the antibody for the dansyl epitope. To determine the antibody exhibited dextran specificity, a competition ELISA was performed by well known methods. The results indicated an apparent association constant of 5 x 105, slightly less that the affinity seen for a wild type anti-dextran lgG3 with the same VH region. Now that the bispecific nature of the antibody had been demonstrated, we examined its half-life in vivo as described in the following example.
Example 6 Half-life studies
BALB/c mice (4-6 weeks old) were administered 10 mg/ml potassium iodide in water for 6 days prior to the experiment in order to saturate the thyroid with cold iodine to reduce any background counts. [125l] labeled protein (1 x 106 cpm of TAAM, TPO, and BSA) in 250 I sterile PBS was injected intraperitoneally into mice in triplicate. Whole body counts were taken at various time points for a total of
400 hours to determine the alpha and beta phase of the count decay. The half-life of the protein was calculated from the slope of the beta curve. The TAAM antibody was found to have a 1 .6 fold longer half life than wild type lgG3 (Figure 4). To determine whether the constant region of the TAAM recombinant
antibody was able to bind to Fc receptors, a cell binding assay was performed as follows.
Example 7 F„ receptor binding assay Human U937 monocytic cells expressing the high affinity FcyR\ receptor were grown in RPMI containing 10% FCS and stimulated with 100 units/ml human interferon for 2-3 days prior to the assay. Cells were harvested by centrifugation at 1 ,000 rpm for 5 min, washed in cold PBS and counted using a hemocytometer. The cells were resuspended at 1 x 107 cells/ml in serum-free DMEM and incubated fpr 2 hours at 37°C. Eppendorf tubes were prepared which contained a constant amount of [125l] labeled recombinant antibody (approximately 20 ng; 1 x 105 cpm) in 50 ml binding buffer (0.1 M HEPES, pH 7.4-7.7, 0.1 2 M NaCl, 5 mM KG, 1 .2 mM MgS04, 1 5 mM acetic acid, 10 mM glucose, 1 % BSA).
Fifty μ\ of the above solution containing varying concentrations of the same unlabeled protein as competitor were added to duplicate tubes. Cells were resuspended in binding buffer at 4-6 x 106/ml and 400 //I total volume was added to each tube. Samples were incubated for 3 hours at 1 °C with constant rotation, pelleted, the pellets carefully washed with cold PBS and counted for 2 min in a gamma counter. The results indicated that the antibody had an affinity for the Fc receptors on U937 cells (Figure 5) with a binding dissociation constant of around
5 x 10'7 M.
To evaluate another function associated with the constant region of antibodies, C1 q binding, the first step in the activation of the complement cascade, was evaluated as described below: Example 8
C1 α binding assay lmmulon-2 microtiter plates (American Scientific) were coated with 100 μl dansyl-coated BSA (substitution ration 40: 1 ; 10 mg/ml in HEPES-buffered saline (HBS)) per well, incubated at 4°C overnight and washed 6 times with HBS containing 0.02% sodium azide. Plates were blocked with 200 /I 3% BSA in HBS.
After blocking, 20 μg of either bispecific or control antibody in HBS (containing 1 % BSA) was added (100 μl/well) in quadruplicate and incubated for 2 hours at room temperature. Wells were washed 6 times with HBS and 100 μ\ 0.25% normal human serum was added for 2 hours at 37°C. Wells were washed and incubated with 100 /I goat anti-human C1 q (1 : 10,000; Atlantic Antibodies) for 1 hour at
37°C. Wells were washed to remove unbound antibodies followed by incubation with 100 μl/well alkaline phosphatase-conjugated swine anti-goat antibody (1 :20,000) for 2 hours at 37°C. Wells were washed to remove unbound antibody and 100 μ\ p-nitrophenyl phosphate (0.5 mg/ml; Sigma) was added and the absorbance read at 410 nm.
The results indicated that the TAAM antibody bound C1 q, although with a decreased efficiency compared to TPO wild type antibody (Figure 6). Since it has been demonstrated that tetravalent, bispecific antibodies can bind Fc receptors and bind C1 q, the first step in complement activation, we anticipate that these antibodies will be useful as therapeutics as described below.
Example 9 Use of tetravalent antibody conjugates to Ivse tumor cells Recombinant bispecific monoclonal antibodies having both anti-CD3 or anti- IL-2 receptor (found on activated T-cells) and anti-tumor cell antigen affinities are produced using the method described in Examples 1 -3. Other T cell surface antigens are also within the scope of the present invention. A variety of tumor cell antigens can be targeted including, but not limited to, the 145 kDa cell surface glycoprotein expressed on human gliomas and small lung carcinomas, the carcinoembryonic antigen expressed on a wide range of tumor cells and the Ley antigen expressed on breast, lung and colon carcinoma.
Peripheral blood mononuclear cells (PBMC) are isolated from the blood of healthy donors or tumor patients by Ficoll-Hypaque gradient centrifugation. The cells are then incubated in culture medium in the presence or absence of 100 units/ml recombinant human IL-2 for 3 days at 37°C. Control cells receive no lL-2. Target tumor cells are labeled with 51Cr and plated in 96 well microtiter plates and about 0.1 -about 100 μg recombinant antibody is added to each well for about 30- about 60 min. Activated T-cells are then added for about 4 hours. Cytolysis is assessed by gamma counting of the cell supernatant after centrifugation. The use of other activating cytokines, including but not limited to, IL-1 , IL-6, and the interferons is also contemplated.
The use of this procedure in vivo is also envisioned. Tetravalent, bispecific antibodies are complexed with T cells. Advantageously, these immune cells may be activated in vitro prior to complex formation. The immune cell-antibody complex is then injected into a mammal, preferably a human, in an amount sufficient to promote tumor cell lysis and tumor regression. Most preferably, the tetravalent
antibody is injected by itself whereupon it promotes the union of immune cells and tumor cells in vivo without the need for prior immune cell-antibody complex formation. The amount of immune cell-antibody complex or of antibody alone administered will depend on the type and size of the carcinoma, the extent of metastasis, the activation state of the immune cell and the affinity of the antibody for the tumor cell antigen. If metastasis has occurred, the administration of more than one tetravalent, bispecific antibody type is also contemplated. The administration of antibodies, either alone or in complex with immune cells, in conjunction with conventional chemotherapy, is also envisioned. Other immune cell types, including, but not limited to, natural killer (NK) and lymphokine-activated killer (LAK) cells are also within the scope of the present invention.
A similar experiment can be performed using an antibody specific for the same aforementioned anti-T cell antigens and for a toxin or chemotherapeutic agent such as ricin or vindesine, respectively. In this embodiment, the bispecific, tetravalent antibody is necessarily complexed to the toxin or chemotherapeutic agent in vitro prior to injection in vivo. The bispecific antibody can then deliver such an agent to tumor cells resulting in tumor cell lysis and tumor regression.
The tetravalency of the recombinant antibody provides a greater binding capacity than bivalent recombinant antibodies, since each end of the molecule can bind two antigens thus delivering twice as much chemotherapeutic agent or toxin to the target cell as would a similar bivalent antibody. Thus, the amount of antibody to be administered could be reduced without reducing its efficacy. In addition, since the antigen combining sites are located on opposite ends of the molecule, this provides greater binding flexibility thus allowing the antibody to bridge greater distances between targets.
The antibody of the present invention can also be used in immunodiagnostics as described below.
Example 10 Use of the tetravalent antibody in immunodiagnostics A bispecific tetravalent antibody is produced by the method described in the examples above having a specificity against both a tumor cell antigen of interest and either a radiolabeled compound, a dye or a protein capable of catalyzing a colorimetric reaction. The labeled antibody can be used to stain cell or tissue sections to determine the presence of a tumor cell antigen. In addition, since certain proteins are released from tumors into the blood, such as prostatic acid
phosphatase from prostate cancer cells, this antibody will be useful in detecting these antigens by enzyme-linked immunosorbent assay (ELISA) or radioimmunoassay, a technique well known in the art. The antibody can also be used to detect viruses and bacteria in body fluids. While particular embodiments of the invention have been described in detail, it will be apparent to those skilled in the art that these embodiments are exemplary, rather than limiting, and the true scope of the invention is that defined in the following claims.
SEQUENCE LISTING
(1) GENERAL INFORMATION:
(i) APPLICANT: The Regents of the University of California
(ii) TITLE OF INVENTION: GENETICALLY ENGINEERED BISPECIFIC TETRAVALENT ANTIBODIES
(iii) NUMBER OF SEQUENCES: 6
(iv) CORRESPONDENCE ADDRESS:
(A) ADDRESSEE: Knobbe, Martens, Olson & Bear
(B) STREET: 620 Newport Center Drive, Sixteenth Floor
(C) CITY: Newport Beach
(D) STATE: CA
(E) COUNTRY: U.S.A.
(F) ZIP: 92660
(v) COMPUTER READABLE FORM:
(A) MEDIUM TYPE: Floppy disk
(B) COMPUTER: IBM PC compatible
(C) OPERATING SYSTEM: PC-DOS/MS-DOS
(D) SOFTWARE: Patentln Release #1.0, Version #1.25
(vi) CURRENT APPLICATION DATA:
(A) APPLICATION NUMBER:
(B) FILING DATE:
(C) CLASSIFICATION:
(viii) ATTORNEY/AGENT INFORMATION:
(A) NAME: Altman, Daniel E.
(B) REGISTRATION NUMBER: 34,114
(C) REFERENCE/DOCKET NUMBER: UCLAO07.007VPC
(ix) TELECOMMUNICATION INFORMATION:
(A) TELEPHONE: (714) 760-0404
(B) TELEFAX: (714) 760-9502
(2) INFORMATION FOR SEQ ID NO:l:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 54 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: CDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO
(vii) IMMEDIATE SOURCE:
(B) CLONE: Primer B
(xi) SEQUENCE DESCRIPTION: SEQ ID Nθ:l: CGACCCACCT CCGCCCGAGC CACCGCCACC TGCAGAGACA GTGACCAGAG TCCC 54
(2) INFORMATION FOR SEQ ID NO:2:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 51 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO
(vii) IMMEDIATE SOURCE:
(B) CLONE: Primer C
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2: GGCGGAGGTG GGTCGGGTGG CGGCGGATCT GATGTTGTGA TGACCCAAAC T 51
(2) INFORMATION FOR SEQ ID NO:3:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 80 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO
(vii) IMMEDIATE SOURCE:
(B) CLONE: Primer A
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3 : GCCCAGCTGG TGGAGGCGGT TCTGAAGTGA AGCTTGAGGA GTCTGGAGGA GGCTTGGTGC 60 AACCTGGAGG TTCCATGAAA 80
(2) INFORMATION FOR SEQ ID NO:4:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 36 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO
(vii) IMMEDIATE SOURCE:
(B) CLONE: Primer D
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4: GGCGAATTCT TAACGTTTTA TTTCCAACTT TGTCCC 36
(2) INFORMATION FOR SEQ ID NO:5:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 782 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO
(vii) IMMEDIATE SOURCE:
(B) CLONE: anti-dansyl SCAB
(ix) FEATURE:
(A) NAME/KEY: prim_transcript
(B) LOCATION: 12..773
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:
GCCCAGCTGG TGGAGGCGGT TCTGAAGTGA AGCTTGAGGA GTCTGGAGGA GGCTTGGTGC 60
AACCTGGAGG TTCCATGAAA CTCTCTTGTG CTACTTCTGG ATTCACTTTT AGTGATGCCT 120
GGATGGACTG GGTCCGCCAG TCTCCAGAGA AGGGGCTTGA GTGGGTTGCT GAAATTAGAA 180
ACAAAGCTAA TAATCATGCA ACATACTATG CTGAGTCTGT GAAAGGGAGG TTCACCATCT 240
CAAGAGATGA TTCCAAAAGG AGAGTGTACC TGCAAATGAA CACCTTAAGA GCTGAAGACA 300
CTGGCATTTA TTACTGTACC GGGATCTACT ATCATTACCC CTGGTTTGCT TACTGGGGCC 360
AAGGGACTCT GGTCACTGTC TCTGCAGGTG GCGGTGGCTC GGGCGGAGGT GGGTCGGGTG 420
GCGGCGGATC TGATGTTGTG ATGACCCAAA CTCCACTCTC CCTGCCTGTC AGTCTTGGAA 480
ATCAAGCCTC CATCTCTTGC AGATCTAGTC AGAGCCTTGT ACACAGTAAT GGAAACACCT 540
ATTTACATTG GTACCTGCAG AAGCCAGGCC AGTCTCCAAA GCTCCTGATC TACAAAGTTT 600
CCAACCGATT TTCTGGGGTC CCAGACAGGT TCAGTGGCAG TGGATCAGGG ACAGATTTCA 660
CACTCAAGAT CAGCAGAGTG GAGGCTGAGG ATCTGGGAGT TTATTTCTGC TCTCAAAGTA 720
CACATGTTCC ATTCACGTTC GGCTCGGGGA CAAAGTTGGA AATAAAACGT TAAGAATTCG 780
GG 782 (2) INFORMATION FOR SEQ ID NO:6:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 253 amino acids
(B) TYPE: amino acid (D) TOPOLOGY: linear
(ii) MOLECULE TYPE: protein
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6 :
Gly Gly Gly Ser Glu Val Lys Leu Glu Glu Ser Gly Gly Gly Leu Val 1 5 10 15
Gln Pro Gly Gly Ser Met Lys Leu Ser Cys Ala Thr Ser Gly Phe Thr 20 25 30
Phe Ser Asp Ala Trp Met Asp Trp Val Arg Gin Ser Pro Glu Lys Gly 35 40 45
Leu Glu Trp Val Ala Glu lie Arg Asn Lys Ala Asn Asn His Ala Thr 50 55 60
Tyr Tyr Ala Glu Ser Val Lys Gly Arg Phe Thr lie Ser Arg Asp Asp 65 70 75 80
Ser Lys Arg Arg Val Tyr Leu Gin Met Asn Thr Leu Arg Ala Glu Asp 85 90 95
Thr Gly lie Tyr Tyr Cys Thr Gly lie Tyr Tyr His Tyr Pro Trp Phe 100 105 110
Ala Tyr Trp Gly Gin Gly Thr Leu Val Thr Val Ser Ala Gly Gly Gly 115 120 125
Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Val Val Met 130 135 140
Thr Gin Thr Pro Leu Ser Leu Pro Val Ser Leu Gly Asn Gin Ala Ser 145 150 155 160 lie Ser Cys Arg Ser Ser Gin Ser Leu Val His Ser Asn Gly Asn Thr 165 170 175
Tyr Leu His Trp Tyr Leu Gin Lys Pro Gly Gin Ser Pro Lys Leu Leu 180 185 190 lie Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro Asp Arg Phe Ser 195 200 205
Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys lie Ser Arg Val Glu 210 215 220
Ala Glu Asp Leu Gly Val Tyr Phe Cys Ser Gin Ser Thr His Val Pro 225 230 235 240
Phe Thr Phe Gly Ser Gly Thr Lys Leu Glu lie Lys Arg 245 250
Claims
WHAT IS CLAIMED IS:
I . A method for the production of a bispecific, tetravalent antibody comprising the steps of:
(a) producing a DNA segment encoding a single chain antibody (SCAB) comprising fused DNA segments encoding variable heavy and light
(VH and VL) immunoglobulin chains;
(b) ligating said SCAB DNA segment to a DNA segment encoding an immunoglobulin G (IgG) constant region;
(c) constructing an expression vector containing said SCAB- constant region ligation fused to a DNA segment encoding a VH region having a different specificity; and
(d) cotransfecting and expressing said vector and a vector containing a DNA segment encoding the VL region of the same specificity as said VH. 2. The method of Claim 1 , wherein the DNA encoding said SCAB comprises the anti-dansyl VH and VL regions.
3. The method of Claim 1 , wherein the DNA encoding said SCAB is produced by PCR overlap extension.
4. The method of Claim 1 , wherein said VH-VL fusion is through a plurality of gly gly gly gly ser linkers.
5. The method of Claim 1 , wherein the DNA sequence encoding said IgG constant region is a human IgG constant region.
6. The method of Claim 1 , wherein said expression vector is eukaryotic. 7. The method of Claim 6, wherein said eukaryotic expression vector is pAH4633.
8. The method of Claim 1 , wherein said VH and VL specificities are anti-dextran.
9. The method of Claim 1 , wherein said cells are mammalian. 10. The method of Claim 9, wherein said mammalian cells are SP2/0.
I I . An isolated tetravalent, bispecific antibody produced by the method of Claim 1 .
1 2. The isolated tetravalent, bispecific antibody of Claim 1 1 , further comprising a catalytic antibody sequence at one end of said antibody.
1 3. An expression vector encoding the bispecific antibody of Claim 1 1 , comprising:
(a) DNA segment I encoding the VH and VL regions joined by a flexible linker; (b) DNA segment II encoding a human IgG constant region fused to said DNA segment I; and
(c) DNA segment III encoding a VH region with a different specificity from the VH region of said DNA segment I.
14. A transformed cell line continuously expressing the bispecific antibody of Claim 1 1 .
1 5. A method for identifying antigens present in a biological sample or expressed on the cell surface comprising: isolating a biological sample of interest; contacting said biological sample with an isolated antibody according to Claim 1 1 having affinity for an antigen of interest at first end of said antibody and affinity for either a radiolabeled compound, a dye or an enzyme able to catalyze a colorimetric reaction at second end of said antibody; and detecting the binding of said antibody to said antigen of interest. 1 6. The recombinant tetravalent antibody of Claim 1 1 for use in targeting immune cells to tumor cells in vivo.
1 7. The recombinant tetravalent antibody of Claim 1 6 in a form suitable for direct injection in vivo.
1 8. The recombinant tetravalent antibody of Claim 1 1 , having anti-toxin specificity at a first end of said antibody and affinity for a tumor cell antigen at a second end of said antibody.
1 9. The recombinant tetravalent antibody of Claim 1 1 , having affinity for an antigen expressed on the immune cell surface at a first end of said antibody and affinity for a tumor cell surface antigen on a second end of said antibody. 20. Use of a recombinant tetravelent antibody according to Claim 1 1 in the preparation of a medicament for treatment of tumor cells.
21 . A method of targeting immune cells to tumor cells comprising the steps of: contacting said immune cells with a recombinant tetravalent antibody according to Claim 1 1 having affinity for an antigen expressed on
the immune cell surface on a first end of said antibody and affinity for a tumor cell surface antigen on a second end of said antibody; and administering said immune cell-antibody complex to tumor cells.
22. The method of Claim 21 , wherein said immune cells are activated with a cytokine.
23. The method of Claim 21 , wherein said immune cells are either cytotoxic T-cells or lymphokine activated killer cells.
24. The method of Claim 21 , wherein said cytokine is selected from the group consisting of: IL-1 , IL-2, 1L-6, interferon a and interferon y. 25. The method of Claim 21 , wherein said cells are in vitro.
26. The method of Claim 21 , wherein said cells are in vivo.
27. A method of targeting activated immune cells to tumor cells comprising directly injecting the isolated tetravalent, bispecific antibody of Claim 1 1 in vivo, wherein said antibody is not a part of an immune cell-antibody complex.
28. A method for targeting toxins or chemotherapeutic agents to tumor cells comprising the steps of: contacting said agent with a recombinant tetravalent antibody according to Claim 1 1 having anti-toxin specificity at a first end of said antibody and affinity for a tumor cell antigen at a second end of said antibody; and administering said toxin-antibody complex to tumor cells.
29. The method of Claim 28, wherein said toxin is selected from the group consisting of: ricin, adriamycin, daunomycin, vindesine, doxorubicin and taxol.
30. The method of Claim 28, wherein said tumor cells are in vitro.
31 . The method of Claim 28, wherein said tumor cells are in vivo.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13455693A | 1993-10-07 | 1993-10-07 | |
US08/134,556 | 1993-10-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1995009917A1 true WO1995009917A1 (en) | 1995-04-13 |
Family
ID=22463888
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1994/011411 WO1995009917A1 (en) | 1993-10-07 | 1994-10-07 | Genetically engineered bispecific tetravalent antibodies |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO1995009917A1 (en) |
Cited By (235)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997030089A1 (en) * | 1996-02-13 | 1997-08-21 | Regents Of The University Of California | Novel antibody-cytokine fusion protein, and methods of making and using the same |
US5837243A (en) * | 1995-06-07 | 1998-11-17 | Medarex, Inc. | Therapeutic compounds comprised of anti-Fc receptor antibodies |
WO2000006605A2 (en) * | 1998-07-28 | 2000-02-10 | Micromet Ag | Heterominibodies |
US6193967B1 (en) | 1992-10-02 | 2001-02-27 | Peter M. Morganelli | Bispecific reagents for redirected targeting of human lipoproteins |
US6306393B1 (en) * | 1997-03-24 | 2001-10-23 | Immunomedics, Inc. | Immunotherapy of B-cell malignancies using anti-CD22 antibodies |
WO2001083525A2 (en) * | 2000-05-03 | 2001-11-08 | Amgen Inc. | Modified peptides, comprising an fc domain, as therapeutic agents |
US6365161B1 (en) | 1995-06-07 | 2002-04-02 | Medarex, Inc. | Therapeutic compounds comprised of anti-FC receptor binding agents |
WO2000024782A3 (en) * | 1998-10-23 | 2002-06-06 | Amgen Inc | Modified peptides, comprising an fc domain, as therapeutic agents |
WO2002096948A2 (en) * | 2001-01-29 | 2002-12-05 | Idec Pharmaceuticals Corporation | Engineered tetravalent antibodies and methods of use |
WO2003002144A1 (en) * | 2001-06-26 | 2003-01-09 | Imclone Systems Incorporated | Bispecific antibodies that bind to vegf receptors |
WO2003011909A1 (en) * | 2001-07-31 | 2003-02-13 | University Of Southampton | Binding agents with differential activity |
EP1361892A1 (en) * | 2001-01-17 | 2003-11-19 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
US6682928B2 (en) | 1997-12-02 | 2004-01-27 | Medarex, Inc. | Cells expressing anti-Fc receptor binding components |
WO2005000899A2 (en) | 2003-06-27 | 2005-01-06 | Biogen Idec Ma Inc. | Modified binding molecules comprising connecting peptides |
US7026326B2 (en) | 2002-05-21 | 2006-04-11 | Amgen Inc. | Substituted heterocyclic compounds and methods of use |
WO2006074399A2 (en) * | 2005-01-05 | 2006-07-13 | Biogen Idec Ma Inc. | Multispecific binding molecules comprising connecting peptides |
WO2006116657A3 (en) * | 2005-04-26 | 2007-05-18 | Glycofi Inc | Single-chain antibody with cleavable linker |
WO2007062466A1 (en) * | 2005-11-29 | 2007-06-07 | The University Of Sydney | Demibodies: dimerisation-activated therapeutic agents |
US7268120B1 (en) | 1997-11-20 | 2007-09-11 | Vical Incorporated | Methods for treating cancer using cytokine-expressing polynucleotides |
EP1928506A2 (en) * | 2005-08-19 | 2008-06-11 | Abbott Laboratories | Dual variable domain immunoglobin and uses thereof |
WO2009018386A1 (en) * | 2007-07-31 | 2009-02-05 | Medimmune, Llc | Multispecific epitope binding proteins and uses thereof |
US7488590B2 (en) | 1998-10-23 | 2009-02-10 | Amgen Inc. | Modified peptides as therapeutic agents |
EP2050764A1 (en) * | 2007-10-15 | 2009-04-22 | sanofi-aventis | Novel polyvalent bispecific antibody format and uses thereof |
EP2056869A2 (en) * | 2006-08-18 | 2009-05-13 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
US7534427B2 (en) * | 2002-12-31 | 2009-05-19 | Immunomedics, Inc. | Immunotherapy of B cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins |
EP2167130A2 (en) * | 2007-07-06 | 2010-03-31 | Trubion Pharmaceuticals, Inc. | Binding peptides having a c-terminally disposed specific binding domain |
WO2010040508A1 (en) | 2008-10-08 | 2010-04-15 | F. Hoffmann-La Roche Ag | Bispecific anti-vegf/anti-ang-2 antibodies |
US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
US7754209B2 (en) | 2003-07-26 | 2010-07-13 | Trubion Pharmaceuticals | Binding constructs and methods for use thereof |
WO2010085590A1 (en) | 2009-01-23 | 2010-07-29 | Biosynexus Incorporated | Opsonic and protective antibodies specific for lipoteichoic acid gram positive bacteria |
WO2010112194A1 (en) | 2009-04-02 | 2010-10-07 | F. Hoffmann-La Roche Ag | Antigen-binding polypeptides and multispecific antibodies comprising them |
WO2010112193A1 (en) | 2009-04-02 | 2010-10-07 | Roche Glycart Ag | Multispecific antibodies comprising full length antibodies and single chain fab fragments |
WO2010115552A1 (en) | 2009-04-07 | 2010-10-14 | Roche Glycart Ag | Bispecific anti-erbb-3/anti-c-met antibodies |
WO2010115553A1 (en) | 2009-04-07 | 2010-10-14 | Roche Glycart Ag | Bispecific anti-erbb-2/anti-c-met antibodies |
WO2010115589A1 (en) | 2009-04-07 | 2010-10-14 | Roche Glycart Ag | Trivalent, bispecific antibodies |
US7829084B2 (en) | 2001-01-17 | 2010-11-09 | Trubion Pharmaceuticals, Inc. | Binding constructs and methods for use thereof |
US7829064B2 (en) | 1999-05-10 | 2010-11-09 | Immunomedics, Inc. | Anti-CD74 immunoconjugates and methods |
WO2011028952A1 (en) * | 2009-09-02 | 2011-03-10 | Xencor, Inc. | Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens |
US7951921B2 (en) | 2003-07-01 | 2011-05-31 | Immunomedics, Inc. | Multivalent carriers of bi-specific antibodies |
WO2011117329A1 (en) | 2010-03-26 | 2011-09-29 | F. Hoffmann-La Roche Ag | Bispecific, bivalent anti-vegf/anti-ang-2 antibodies |
WO2011117330A1 (en) | 2010-03-26 | 2011-09-29 | Roche Glycart Ag | Bispecific antibodies |
US8119101B2 (en) | 1999-05-10 | 2012-02-21 | The Ohio State University | Anti-CD74 immunoconjugates and methods of use |
AU2008200400B2 (en) * | 2001-01-17 | 2012-06-07 | Aptevo Research And Development Llc | Binding domain-immunoglobulin fusion proteins |
EP2500353A3 (en) * | 2005-08-19 | 2012-10-10 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
US8333966B2 (en) | 2008-04-11 | 2012-12-18 | Emergent Product Development Seattle, Llc | CD37 immunotherapeutics and uses thereof |
US8383081B2 (en) | 1999-05-10 | 2013-02-26 | Immunomedics, Inc. | Anti-CD74 immunoconjugates and methods of use |
US8409577B2 (en) | 2006-06-12 | 2013-04-02 | Emergent Product Development Seattle, Llc | Single chain multivalent binding proteins with effector function |
WO2013101909A1 (en) * | 2011-12-27 | 2013-07-04 | Development Center For Biotechnology | Light chain-bridged bispecific antibody |
WO2013150043A1 (en) | 2012-04-05 | 2013-10-10 | F. Hoffmann-La Roche Ag | Bispecific antibodies against human tweak and human il17 and uses thereof |
WO2013158577A1 (en) | 2012-04-20 | 2013-10-24 | Eli Lilly And Company | Anti-baff-anti-il-17 bispecific antibodies |
US8586714B2 (en) | 2009-09-01 | 2013-11-19 | Abbvie, Inc. | Dual variable domain immunoglobulins and uses thereof |
WO2014006124A1 (en) | 2012-07-04 | 2014-01-09 | F. Hoffmann-La Roche Ag | Covalently linked antigen-antibody conjugates |
US8629246B2 (en) | 2007-09-26 | 2014-01-14 | Ucb Pharma S.A. | Dual specificity antibody fusions |
US8716450B2 (en) | 2009-10-15 | 2014-05-06 | Abbvie Inc. | Dual variable domain immunoglobulins and uses thereof |
US8722859B2 (en) | 2000-04-11 | 2014-05-13 | Genentech, Inc. | Multivalent antibodies and uses therefor |
US8722855B2 (en) | 2009-10-28 | 2014-05-13 | Abbvie Inc. | Dual variable domain immunoglobulins and uses thereof |
US8735546B2 (en) | 2010-08-03 | 2014-05-27 | Abbvie Inc. | Dual variable domain immunoglobulins and uses thereof |
US8796424B2 (en) | 2009-05-27 | 2014-08-05 | Hoffmann-La Roche Inc. | Tri- or tetraspecific antibodies |
US8822645B2 (en) | 2008-07-08 | 2014-09-02 | Abbvie Inc. | Prostaglandin E2 dual variable domain immunoglobulins and uses thereof |
WO2014137961A1 (en) | 2013-03-08 | 2014-09-12 | Eli Lilly And Company | Anti-tnf-anti-il-17 bispecific antibodies |
US8871216B2 (en) | 2005-04-06 | 2014-10-28 | Ibc Pharmaceuticals, Inc. | Multiple signaling pathways induced by hexvalent, monospecific and bispecific antibodies for enhanced toxicity to B-cell lymphomas and other diseases |
US8883160B2 (en) | 2004-02-13 | 2014-11-11 | Ibc Pharmaceuticals, Inc. | Dock-and-lock (DNL) complexes for therapeutic and diagnostic use |
US8906378B2 (en) | 2005-04-06 | 2014-12-09 | Ibc Pharmaceuticals, Inc. | Combination therapy with anti-CD74 antibodies provides enhanced toxicity to malignancies, autoimmune disease and other diseases |
CN104311670A (en) * | 2014-04-23 | 2015-01-28 | 哈尔滨博翱生物医药技术开发有限公司 | Fused polypeptide for IL-17 and TNF[alpha], and application thereof |
US20150044216A1 (en) * | 2013-08-06 | 2015-02-12 | Bio-Thera Solutions, Ltd. | Bispecific antibodies |
US8987418B2 (en) | 2013-03-15 | 2015-03-24 | Abbvie Inc. | Dual specific binding proteins directed against IL-1β and/or IL-17 |
US9005612B2 (en) | 2001-01-17 | 2015-04-14 | Emergent Product Development Seattle, Llc | Binding domain-immunoglobulin fusion proteins |
US9029508B2 (en) | 2008-04-29 | 2015-05-12 | Abbvie Inc. | Dual variable domain immunoglobulins and uses thereof |
US9028833B2 (en) | 2012-12-13 | 2015-05-12 | Immunomedics, Inc. | Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity |
US9035027B2 (en) | 2008-06-03 | 2015-05-19 | Abbvie Inc. | Dual variable domain immunoglobulins and uses thereof |
US9046513B2 (en) | 2010-08-26 | 2015-06-02 | Abbvie Inc. | Dual variable domain immunoglobulins and uses thereof |
US9045551B2 (en) | 2012-11-01 | 2015-06-02 | Abbvie Inc. | Anti-DLL4/VEGF dual variable domain immunoglobulin and uses thereof |
WO2015100104A1 (en) | 2013-12-23 | 2015-07-02 | Eli Lilly And Company | Multifunctional antibodies binding to egfr and met |
WO2015101589A1 (en) | 2014-01-03 | 2015-07-09 | F. Hoffmann-La Roche Ag | Covalently linked polypeptide toxin-antibody conjugates |
WO2015101587A1 (en) | 2014-01-03 | 2015-07-09 | F. Hoffmann-La Roche Ag | Covalently linked helicar-anti-helicar antibody conjugates and uses thereof |
WO2015101586A1 (en) | 2014-01-03 | 2015-07-09 | F. Hoffmann-La Roche Ag | Bispecific anti-hapten/anti-blood brain barrier receptor antibodies, complexes thereof and their use as blood brain barrier shuttles |
US9109026B2 (en) | 2008-06-03 | 2015-08-18 | Abbvie, Inc. | Dual variable domain immunoglobulins and uses thereof |
US9107960B2 (en) | 2012-12-13 | 2015-08-18 | Immunimedics, Inc. | Antibody-SN-38 immunoconjugates with a CL2A linker |
US9114175B2 (en) | 2005-08-12 | 2015-08-25 | Amgen Inc. | Modified Fc molecules |
US9120870B2 (en) | 2011-12-30 | 2015-09-01 | Abbvie Inc. | Dual specific binding proteins directed against IL-13 and IL-17 |
WO2015138920A1 (en) | 2014-03-14 | 2015-09-17 | Novartis Ag | Antibody molecules to lag-3 and uses thereof |
WO2015142675A2 (en) | 2014-03-15 | 2015-09-24 | Novartis Ag | Treatment of cancer using chimeric antigen receptor |
US9145450B2 (en) | 1998-10-23 | 2015-09-29 | Amgen Inc. | Thrombopoietic compounds |
WO2015153765A1 (en) | 2014-04-01 | 2015-10-08 | Adimab, Llc | Multispecific antibody analogs comprising a common light chain, and methods of their preparation and use |
EP2281845A4 (en) * | 2008-04-25 | 2015-11-04 | Kyowa Hakko Kirin Co Ltd | Stable polyvalent antibody |
US9192664B2 (en) | 2011-12-05 | 2015-11-24 | Immunomedics, Inc. | Therapeutic use of anti-CD22 antibodies for inducing trogocytosis |
US9220791B2 (en) | 2008-11-06 | 2015-12-29 | University Of Washington | Bispecific intracellular delivery vehicles |
WO2016014553A1 (en) | 2014-07-21 | 2016-01-28 | Novartis Ag | Sortase synthesized chimeric antigen receptors |
WO2016014530A1 (en) | 2014-07-21 | 2016-01-28 | Novartis Ag | Combinations of low, immune enhancing. doses of mtor inhibitors and cars |
WO2016014565A2 (en) | 2014-07-21 | 2016-01-28 | Novartis Ag | Treatment of cancer using humanized anti-bcma chimeric antigen receptor |
WO2016025880A1 (en) | 2014-08-14 | 2016-02-18 | Novartis Ag | Treatment of cancer using gfr alpha-4 chimeric antigen receptor |
US9266967B2 (en) | 2007-12-21 | 2016-02-23 | Hoffmann-La Roche, Inc. | Bivalent, bispecific antibodies |
WO2016044605A1 (en) | 2014-09-17 | 2016-03-24 | Beatty, Gregory | Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy |
WO2016061142A1 (en) | 2014-10-14 | 2016-04-21 | Novartis Ag | Antibody molecules to pd-l1 and uses thereof |
WO2016090034A2 (en) | 2014-12-03 | 2016-06-09 | Novartis Ag | Methods for b cell preconditioning in car therapy |
WO2016160476A1 (en) | 2015-04-03 | 2016-10-06 | Eli Lilly And Company | Anti-cd20- / anti-baff bispecific antibodies |
WO2016164731A2 (en) | 2015-04-08 | 2016-10-13 | Novartis Ag | Cd20 therapies, cd22 therapies, and combination therapies with a cd19 chimeric antigen receptor (car) - expressing cell |
WO2016172583A1 (en) | 2015-04-23 | 2016-10-27 | Novartis Ag | Treatment of cancer using chimeric antigen receptor and protein kinase a blocker |
US9492566B2 (en) | 2012-12-13 | 2016-11-15 | Immunomedics, Inc. | Antibody-drug conjugates and uses thereof |
US9550838B2 (en) | 2004-02-13 | 2017-01-24 | Ibc Pharmaceuticals, Inc. | Dock-and-lock (DNL) complexes for therapeutic and diagnostic use |
WO2017019894A1 (en) | 2015-07-29 | 2017-02-02 | Novartis Ag | Combination therapies comprising antibody molecules to lag-3 |
WO2017019897A1 (en) | 2015-07-29 | 2017-02-02 | Novartis Ag | Combination therapies comprising antibody molecules to tim-3 |
US9676845B2 (en) | 2009-06-16 | 2017-06-13 | Hoffmann-La Roche, Inc. | Bispecific antigen binding proteins |
WO2017106810A2 (en) | 2015-12-17 | 2017-06-22 | Novartis Ag | Combination of c-met inhibitor with antibody molecule to pd-1 and uses thereof |
WO2017106656A1 (en) | 2015-12-17 | 2017-06-22 | Novartis Ag | Antibody molecules to pd-1 and uses thereof |
US9688758B2 (en) | 2012-02-10 | 2017-06-27 | Genentech, Inc. | Single-chain antibodies and other heteromultimers |
US9695233B2 (en) | 2012-07-13 | 2017-07-04 | Roche Glycart Ag | Bispecific anti-VEGF/anti-ANG-2 antibodies and their use in the treatment of ocular vascular diseases |
US9707302B2 (en) | 2013-07-23 | 2017-07-18 | Immunomedics, Inc. | Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer |
WO2017125897A1 (en) | 2016-01-21 | 2017-07-27 | Novartis Ag | Multispecific molecules targeting cll-1 |
US9718884B2 (en) | 2014-11-05 | 2017-08-01 | Eli Lilly And Company | Anti-TNF-/anti-IL-23 bispecific antibodies |
WO2017149515A1 (en) | 2016-03-04 | 2017-09-08 | Novartis Ag | Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore |
US9757458B2 (en) | 2011-12-05 | 2017-09-12 | Immunomedics, Inc. | Crosslinking of CD22 by epratuzumab triggers BCR signaling and caspase-dependent apoptosis in hematopoietic cancer cells |
US9765153B2 (en) | 2012-07-04 | 2017-09-19 | Hoffmann-La Roche Inc. | Anti-biotin antibodies and methods of use |
US9770517B2 (en) | 2002-03-01 | 2017-09-26 | Immunomedics, Inc. | Anti-Trop-2 antibody-drug conjugates and uses thereof |
WO2017165464A1 (en) | 2016-03-21 | 2017-09-28 | Elstar Therapeutics, Inc. | Multispecific and multifunctional molecules and uses thereof |
WO2017165683A1 (en) | 2016-03-23 | 2017-09-28 | Novartis Ag | Cell secreted minibodies and uses thereof |
WO2017181119A2 (en) | 2016-04-15 | 2017-10-19 | Novartis Ag | Compositions and methods for selective protein expression |
US9797907B2 (en) | 2015-04-22 | 2017-10-24 | Immunomedics, Inc. | Isolation, detection, diagnosis and/or characterization of circulating Trop-2-positive cancer cells |
WO2017210617A2 (en) | 2016-06-02 | 2017-12-07 | Porter, David, L. | Therapeutic regimens for chimeric antigen receptor (car)- expressing cells |
US9840554B2 (en) | 2015-06-15 | 2017-12-12 | Abbvie Inc. | Antibodies against platelet-derived growth factor (PDGF) |
WO2018013918A2 (en) | 2016-07-15 | 2018-01-18 | Novartis Ag | Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitor |
US9879095B2 (en) | 2010-08-24 | 2018-01-30 | Hoffman-La Roche Inc. | Bispecific antibodies comprising a disulfide stabilized-Fv fragment |
WO2018023025A1 (en) | 2016-07-28 | 2018-02-01 | Novartis Ag | Combination therapies of chimeric antigen receptors adn pd-1 inhibitors |
US9884921B2 (en) | 2014-07-01 | 2018-02-06 | Pfizer Inc. | Bispecific heterodimeric diabodies and uses thereof |
WO2018026819A2 (en) | 2016-08-01 | 2018-02-08 | Novartis Ag | Treatment of cancer using a chimeric antigen receptor in combination with an inhibitor of a pro-m2 macrophage molecule |
US9925272B2 (en) | 2012-07-04 | 2018-03-27 | Hoffmann-La Roche Inc. | Anti-theophylline antibodies and methods of use |
US9931417B2 (en) | 2012-12-13 | 2018-04-03 | Immunomedics, Inc. | Antibody-SN-38 immunoconjugates with a CL2A linker |
WO2018067992A1 (en) | 2016-10-07 | 2018-04-12 | Novartis Ag | Chimeric antigen receptors for the treatment of cancer |
US9982036B2 (en) | 2011-02-28 | 2018-05-29 | Hoffmann-La Roche Inc. | Dual FC antigen binding proteins |
US9994646B2 (en) | 2009-09-16 | 2018-06-12 | Genentech, Inc. | Coiled coil and/or tether containing protein complexes and uses thereof |
WO2018140725A1 (en) | 2017-01-26 | 2018-08-02 | Novartis Ag | Cd28 compositions and methods for chimeric antigen receptor therapy |
WO2018151820A1 (en) | 2017-02-16 | 2018-08-23 | Elstar Therapeutics, Inc. | Multifunctional molecules comprising a trimeric ligand and uses thereof |
US10058621B2 (en) | 2015-06-25 | 2018-08-28 | Immunomedics, Inc. | Combination therapy with anti-HLA-DR antibodies and kinase inhibitors in hematopoietic cancers |
WO2018160731A1 (en) | 2017-02-28 | 2018-09-07 | Novartis Ag | Shp inhibitor compositions and uses for chimeric antigen receptor therapy |
US10093733B2 (en) | 2014-12-11 | 2018-10-09 | Abbvie Inc. | LRP-8 binding dual variable domain immunoglobulin proteins |
US10106612B2 (en) | 2012-06-27 | 2018-10-23 | Hoffmann-La Roche Inc. | Method for selection and production of tailor-made highly selective and multi-specific targeting entities containing at least two different binding entities and uses thereof |
WO2018201051A1 (en) | 2017-04-28 | 2018-11-01 | Novartis Ag | Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor |
WO2018201056A1 (en) | 2017-04-28 | 2018-11-01 | Novartis Ag | Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor |
US10138293B2 (en) | 2007-12-21 | 2018-11-27 | Hoffmann-La Roche, Inc. | Bivalent, bispecific antibodies |
US10137196B2 (en) | 2012-12-13 | 2018-11-27 | Immunomedics, Inc. | Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity |
US10143748B2 (en) | 2005-07-25 | 2018-12-04 | Aptevo Research And Development Llc | B-cell reduction using CD37-specific and CD20-specific binding molecules |
WO2018222901A1 (en) | 2017-05-31 | 2018-12-06 | Elstar Therapeutics, Inc. | Multispecific molecules that bind to myeloproliferative leukemia (mpl) protein and uses thereof |
WO2018237157A1 (en) | 2017-06-22 | 2018-12-27 | Novartis Ag | Antibody molecules to cd73 and uses thereof |
WO2019006007A1 (en) | 2017-06-27 | 2019-01-03 | Novartis Ag | Dosage regimens for anti-tim-3 antibodies and uses thereof |
WO2019018730A1 (en) | 2017-07-20 | 2019-01-24 | Novartis Ag | Dosage regimens of anti-lag-3 antibodies and uses thereof |
US10195175B2 (en) | 2015-06-25 | 2019-02-05 | Immunomedics, Inc. | Synergistic effect of anti-Trop-2 antibody-drug conjugate in combination therapy for triple-negative breast cancer when used with microtubule inhibitors or PARP inhibitors |
US10206918B2 (en) | 2012-12-13 | 2019-02-19 | Immunomedics, Inc. | Efficacy of anti-HLA-DR antiboddy drug conjugate IMMU-140 (hL243-CL2A-SN-38) in HLA-DR positive cancers |
WO2019035938A1 (en) | 2017-08-16 | 2019-02-21 | Elstar Therapeutics, Inc. | Multispecific molecules that bind to bcma and uses thereof |
US10251952B2 (en) | 2014-06-26 | 2019-04-09 | Hoffmann-La Roche Inc. | Humanized anti-tau(pS422) antibody brain shuttles and use thereof |
US10266605B2 (en) | 2016-04-27 | 2019-04-23 | Immunomedics, Inc. | Efficacy of anti-trop-2-SN-38 antibody drug conjugates for therapy of tumors relapsed/refractory to checkpoint inhibitors |
WO2019089798A1 (en) | 2017-10-31 | 2019-05-09 | Novartis Ag | Anti-car compositions and methods |
WO2019099838A1 (en) | 2017-11-16 | 2019-05-23 | Novartis Ag | Combination therapies |
US10323099B2 (en) | 2013-10-11 | 2019-06-18 | Hoffmann-La Roche Inc. | Multispecific domain exchanged common variable light chain antibodies |
EP3514179A1 (en) | 2014-01-24 | 2019-07-24 | Dana-Farber Cancer Institute, Inc. | Antibody molecules to pd-1 and uses thereof |
WO2019152660A1 (en) | 2018-01-31 | 2019-08-08 | Novartis Ag | Combination therapy using a chimeric antigen receptor |
US10407513B2 (en) | 2008-09-26 | 2019-09-10 | Ucb Biopharma Sprl | Biological products |
US10413539B2 (en) | 2012-12-13 | 2019-09-17 | Immunomedics, Inc. | Therapy for metastatic urothelial cancer with the antibody-drug conjugate, sacituzumab govitecan (IMMU-132) |
WO2019178364A2 (en) | 2018-03-14 | 2019-09-19 | Elstar Therapeutics, Inc. | Multifunctional molecules and uses thereof |
WO2019178362A1 (en) | 2018-03-14 | 2019-09-19 | Elstar Therapeutics, Inc. | Multifunctional molecules that bind to calreticulin and uses thereof |
WO2019200229A1 (en) | 2018-04-13 | 2019-10-17 | Novartis Ag | Dosage regimens for anti-pd-l1 antibodies and uses thereof |
WO2019210153A1 (en) | 2018-04-27 | 2019-10-31 | Novartis Ag | Car t cell therapies with enhanced efficacy |
US10465000B2 (en) | 2013-12-20 | 2019-11-05 | Hoffmann-La Roche Inc. | Humanized anti-Tau(pS422) antibodies and methods of use |
WO2019226658A1 (en) | 2018-05-21 | 2019-11-28 | Compass Therapeutics Llc | Multispecific antigen-binding compositions and methods of use |
WO2019227003A1 (en) | 2018-05-25 | 2019-11-28 | Novartis Ag | Combination therapy with chimeric antigen receptor (car) therapies |
WO2019226617A1 (en) | 2018-05-21 | 2019-11-28 | Compass Therapeutics Llc | Compositions and methods for enhancing the killing of target cells by nk cells |
WO2019232244A2 (en) | 2018-05-31 | 2019-12-05 | Novartis Ag | Antibody molecules to cd73 and uses thereof |
WO2019241426A1 (en) | 2018-06-13 | 2019-12-19 | Novartis Ag | Bcma chimeric antigen receptors and uses thereof |
WO2019246293A2 (en) | 2018-06-19 | 2019-12-26 | Atarga, Llc | Antibody molecules to complement component 5 and uses thereof |
WO2020010250A2 (en) | 2018-07-03 | 2020-01-09 | Elstar Therapeutics, Inc. | Anti-tcr antibody molecules and uses thereof |
WO2020012337A1 (en) | 2018-07-10 | 2020-01-16 | Novartis Ag | 3-(5-amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and their use in the treatment of i karos family zinc finger 2 (ikzf2)-dependent diseases |
WO2020021465A1 (en) | 2018-07-25 | 2020-01-30 | Advanced Accelerator Applications (Italy) S.R.L. | Method of treatment of neuroendocrine tumors |
US10611825B2 (en) | 2011-02-28 | 2020-04-07 | Hoffmann La-Roche Inc. | Monovalent antigen binding proteins |
US10633457B2 (en) | 2014-12-03 | 2020-04-28 | Hoffmann-La Roche Inc. | Multispecific antibodies |
EP3660042A1 (en) | 2014-07-31 | 2020-06-03 | Novartis AG | Subset-optimized chimeric antigen receptor-containing t-cells |
WO2020128898A1 (en) | 2018-12-20 | 2020-06-25 | Novartis Ag | Pharmaceutical combinations |
WO2020128972A1 (en) | 2018-12-20 | 2020-06-25 | Novartis Ag | Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives |
US10744129B2 (en) | 2012-12-13 | 2020-08-18 | Immunomedics, Inc. | Therapy of small-cell lung cancer (SCLC) with a topoisomerase-I inhibiting antibody-drug conjugate (ADC) targeting Trop-2 |
WO2020165868A1 (en) | 2019-02-15 | 2020-08-20 | Perkinelmer Cellular Technologies Germany Gmbh | Low-power microscope-objective pre-scan and high-power microscope-objective scan in x,y and z-direction for imaging objects such as cells using a microscope |
WO2020165833A1 (en) | 2019-02-15 | 2020-08-20 | Novartis Ag | 3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
WO2020165834A1 (en) | 2019-02-15 | 2020-08-20 | Novartis Ag | Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
WO2020172605A1 (en) | 2019-02-21 | 2020-08-27 | Elstar Therapeutics, Inc. | Antibody molecules that bind to nkp30 and uses thereof |
WO2020172596A1 (en) | 2019-02-21 | 2020-08-27 | Elstar Therapeutics, Inc. | Anti-tcr antibody molecules and thereof |
WO2020172601A1 (en) | 2019-02-21 | 2020-08-27 | Elstar Therapeutics, Inc. | Multifunctional molecules that bind to calreticulin and uses thereof |
WO2020172598A1 (en) | 2019-02-21 | 2020-08-27 | Elstar Therapeutics, Inc. | Multifunctional molecules that bind to t cells and uses thereof to treat autoimmune disorders |
WO2020172571A1 (en) | 2019-02-21 | 2020-08-27 | Elstar Therapeutics, Inc. | Multifunctional molecules that bind to t cell related cancer cells and uses thereof |
WO2020172553A1 (en) | 2019-02-22 | 2020-08-27 | Novartis Ag | Combination therapies of egfrviii chimeric antigen receptors and pd-1 inhibitors |
EP3712171A1 (en) | 2014-08-19 | 2020-09-23 | Novartis AG | Treatment of cancer using a cd123 chimeric antigen receptor |
WO2020205523A1 (en) | 2019-03-29 | 2020-10-08 | Atarga, Llc | Anti fgf23 antibody |
US10799597B2 (en) | 2017-04-03 | 2020-10-13 | Immunomedics, Inc. | Subcutaneous administration of antibody-drug conjugates for cancer therapy |
EP3722316A1 (en) | 2014-07-21 | 2020-10-14 | Novartis AG | Treatment of cancer using a cd33 chimeric antigen receptor |
US10822402B2 (en) | 2015-06-24 | 2020-11-03 | Hoffmann-La Roche Inc. | Humanized anti-tau(pS422) antibodies and methods of use |
US10918734B2 (en) | 2017-03-27 | 2021-02-16 | Immunomedics, Inc. | Treatment of high Trop-2 expressing triple negative breast cancer (TNBC) with sacituzumab govitecan (IMMU-132) overcomes homologous recombination repair (HRR) rescue mediated by Rad51 |
US10954305B2 (en) | 2016-02-10 | 2021-03-23 | Immunomedics, Inc. | Combination of ABCG2 inhibitors with sacituzumab govitecan (IMMU-132) overcomes resistance to SN-38 in Trop-2 expressing cancers |
US10973920B2 (en) | 2014-06-30 | 2021-04-13 | Glykos Finland Oy | Saccharide derivative of a toxic payload and antibody conjugates thereof |
WO2021079188A1 (en) | 2019-10-21 | 2021-04-29 | Novartis Ag | Combination therapies with venetoclax and tim-3 inhibitors |
WO2021079195A1 (en) | 2019-10-21 | 2021-04-29 | Novartis Ag | Tim-3 inhibitors and uses thereof |
WO2021108661A2 (en) | 2019-11-26 | 2021-06-03 | Novartis Ag | Chimeric antigen receptors and uses thereof |
WO2021123902A1 (en) | 2019-12-20 | 2021-06-24 | Novartis Ag | Combination of anti tim-3 antibody mbg453 and anti tgf-beta antibody nis793, with or without decitabine or the anti pd-1 antibody spartalizumab, for treating myelofibrosis and myelodysplastic syndrome |
US11046769B2 (en) | 2018-11-13 | 2021-06-29 | Compass Therapeutics Llc | Multispecific binding constructs against checkpoint molecules and uses thereof |
WO2021138407A2 (en) | 2020-01-03 | 2021-07-08 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to cd33 and uses thereof |
WO2021144657A1 (en) | 2020-01-17 | 2021-07-22 | Novartis Ag | Combination comprising a tim-3 inhibitor and a hypomethylating agent for use in treating myelodysplastic syndrome or chronic myelomonocytic leukemia |
WO2021146636A1 (en) | 2020-01-17 | 2021-07-22 | Becton, Dickinson And Company | Methods and compositions for single cell secretomics |
WO2021173995A2 (en) | 2020-02-27 | 2021-09-02 | Novartis Ag | Methods of making chimeric antigen receptor-expressing cells |
WO2021217085A1 (en) | 2020-04-24 | 2021-10-28 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to t cell related cancer cells and uses thereof |
WO2021260528A1 (en) | 2020-06-23 | 2021-12-30 | Novartis Ag | Dosing regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives |
WO2022013787A1 (en) | 2020-07-16 | 2022-01-20 | Novartis Ag | Anti-betacellulin antibodies, fragments thereof, and multi-specific binding molecules |
WO2022026592A2 (en) | 2020-07-28 | 2022-02-03 | Celltas Bio, Inc. | Antibody molecules to coronavirus and uses thereof |
WO2022029573A1 (en) | 2020-08-03 | 2022-02-10 | Novartis Ag | Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
US11253606B2 (en) | 2013-07-23 | 2022-02-22 | Immunomedics, Inc. | Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, Bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer |
WO2022046922A2 (en) | 2020-08-26 | 2022-03-03 | Marengo Therapeutics, Inc. | Antibody molecules that bind to nkp30 and uses thereof |
WO2022047046A1 (en) | 2020-08-26 | 2022-03-03 | Marengo Therapeutics, Inc. | Methods of detecting trbc1 or trbc2 |
WO2022043558A1 (en) | 2020-08-31 | 2022-03-03 | Advanced Accelerator Applications International Sa | Method of treating psma-expressing cancers |
WO2022046920A2 (en) | 2020-08-26 | 2022-03-03 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to calreticulin and uses thereof |
WO2022043557A1 (en) | 2020-08-31 | 2022-03-03 | Advanced Accelerator Applications International Sa | Method of treating psma-expressing cancers |
WO2022097065A2 (en) | 2020-11-06 | 2022-05-12 | Novartis Ag | ANTIBODY Fc VARIANTS |
US11332541B2 (en) | 2018-06-09 | 2022-05-17 | Boehringer Ingelheim International Gmbh | Multi-specific binding proteins for cancer treatment |
WO2022104061A1 (en) | 2020-11-13 | 2022-05-19 | Novartis Ag | Combination therapies with chimeric antigen receptor (car)-expressing cells |
US11352426B2 (en) | 2015-09-21 | 2022-06-07 | Aptevo Research And Development Llc | CD3 binding polypeptides |
WO2022162569A1 (en) | 2021-01-29 | 2022-08-04 | Novartis Ag | Dosage regimes for anti-cd73 and anti-entpd2 antibodies and uses thereof |
US11421022B2 (en) | 2012-06-27 | 2022-08-23 | Hoffmann-La Roche Inc. | Method for making antibody Fc-region conjugates comprising at least one binding entity that specifically binds to a target and uses thereof |
WO2022216993A2 (en) | 2021-04-08 | 2022-10-13 | Marengo Therapeutics, Inc. | Multifuntional molecules binding to tcr and uses thereof |
WO2022215011A1 (en) | 2021-04-07 | 2022-10-13 | Novartis Ag | USES OF ANTI-TGFβ ANTIBODIES AND OTHER THERAPEUTIC AGENTS FOR THE TREATMENT OF PROLIFERATIVE DISEASES |
WO2022243846A1 (en) | 2021-05-18 | 2022-11-24 | Novartis Ag | Combination therapies |
WO2023044483A2 (en) | 2021-09-20 | 2023-03-23 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of her2 positive cancer |
US11618790B2 (en) | 2010-12-23 | 2023-04-04 | Hoffmann-La Roche Inc. | Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery |
WO2023092004A1 (en) | 2021-11-17 | 2023-05-25 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of tau-related disorders |
US11718679B2 (en) | 2017-10-31 | 2023-08-08 | Compass Therapeutics Llc | CD137 antibodies and PD-1 antagonists and uses thereof |
WO2023150778A1 (en) | 2022-02-07 | 2023-08-10 | Visterra, Inc. | Anti-idiotype antibody molecules and uses thereof |
US11752207B2 (en) | 2017-07-11 | 2023-09-12 | Compass Therapeutics Llc | Agonist antibodies that bind human CD137 and uses thereof |
WO2023209568A1 (en) | 2022-04-26 | 2023-11-02 | Novartis Ag | Multispecific antibodies targeting il-13 and il-18 |
RU2807346C2 (en) * | 2019-07-11 | 2023-11-14 | УХАНЬ АйЗиАй БАЙОФАРМА КО., ЛТД. | Tetravalent symmetrical bispecific antibodies |
WO2023220695A2 (en) | 2022-05-13 | 2023-11-16 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of her2 positive cancer |
US11851497B2 (en) | 2017-11-20 | 2023-12-26 | Compass Therapeutics Llc | CD137 antibodies and tumor antigen-targeting antibodies and uses thereof |
WO2024030976A2 (en) | 2022-08-03 | 2024-02-08 | Voyager Therapeutics, Inc. | Compositions and methods for crossing the blood brain barrier |
EP4324518A2 (en) | 2014-01-31 | 2024-02-21 | Novartis AG | Antibody molecules to tim-3 and uses thereof |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0404097A2 (en) * | 1989-06-22 | 1990-12-27 | BEHRINGWERKE Aktiengesellschaft | Bispecific and oligospecific, mono- and oligovalent receptors, production and applications thereof |
EP0517024A2 (en) * | 1991-06-03 | 1992-12-09 | BEHRINGWERKE Aktiengesellschaft | Tetravalent bispecific receptors, their preparation and use |
WO1993011161A1 (en) * | 1991-11-25 | 1993-06-10 | Enzon, Inc. | Multivalent antigen-binding proteins |
-
1994
- 1994-10-07 WO PCT/US1994/011411 patent/WO1995009917A1/en active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0404097A2 (en) * | 1989-06-22 | 1990-12-27 | BEHRINGWERKE Aktiengesellschaft | Bispecific and oligospecific, mono- and oligovalent receptors, production and applications thereof |
EP0517024A2 (en) * | 1991-06-03 | 1992-12-09 | BEHRINGWERKE Aktiengesellschaft | Tetravalent bispecific receptors, their preparation and use |
WO1993011161A1 (en) * | 1991-11-25 | 1993-06-10 | Enzon, Inc. | Multivalent antigen-binding proteins |
Non-Patent Citations (2)
Title |
---|
H. TADA ET AL.: "Expression and characterization of a chimeric bispecific antibody against fibrin and against urokinase-type plasminogen activator.", JOURNAL OF BIOTECHNOLOGY, vol. 33, no. 2, 1994, AMSTERDAM, THE NETHERLANDS, pages 157 - 174 * |
M. HAYDEN ET AL.: "Single-chain mono- and bispecific antibody derivatives with novel biological properties and antitumour activity from a COS cell transient expression system.", THERAPEUTIC IMMUNOLOGY, vol. 1, no. 1, January 1994 (1994-01-01), OXFORD, GB, pages 3 - 15 * |
Cited By (385)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6193967B1 (en) | 1992-10-02 | 2001-02-27 | Peter M. Morganelli | Bispecific reagents for redirected targeting of human lipoproteins |
US6365161B1 (en) | 1995-06-07 | 2002-04-02 | Medarex, Inc. | Therapeutic compounds comprised of anti-FC receptor binding agents |
US6410690B1 (en) | 1995-06-07 | 2002-06-25 | Medarex, Inc. | Therapeutic compounds comprised of anti-Fc receptor antibodies |
US6395272B1 (en) | 1995-06-07 | 2002-05-28 | Mederex, Inc. | Therapeutic compounds comprised of anti-Fc receptor antibodies |
US5837243A (en) * | 1995-06-07 | 1998-11-17 | Medarex, Inc. | Therapeutic compounds comprised of anti-Fc receptor antibodies |
US6270765B1 (en) | 1995-06-07 | 2001-08-07 | Medarex, Inc. | Therapeutic compounds comprised of anti-Fc receptor antibodies |
WO1997030089A1 (en) * | 1996-02-13 | 1997-08-21 | Regents Of The University Of California | Novel antibody-cytokine fusion protein, and methods of making and using the same |
US6306393B1 (en) * | 1997-03-24 | 2001-10-23 | Immunomedics, Inc. | Immunotherapy of B-cell malignancies using anti-CD22 antibodies |
US7837995B2 (en) | 1997-03-24 | 2010-11-23 | Immunomedics, Inc. | Immunotherapy of B-cell malignancies using anti-CD22 antibodies |
US7910103B2 (en) | 1997-03-24 | 2011-03-22 | Immunomedics, Inc. | Immunotherapy of B-cell malignancies using anti-CD22 antibodies |
US7939073B2 (en) | 1997-03-24 | 2011-05-10 | Immunomedics, Inc. | Immunotherapy of B-cell malignancies using anti-CD22 antibodies |
US8105596B2 (en) | 1997-03-24 | 2012-01-31 | Immunomedics, Inc. | Immunotherapy of B-cell malignancies using anti-CD22 antibodies |
US7268120B1 (en) | 1997-11-20 | 2007-09-11 | Vical Incorporated | Methods for treating cancer using cytokine-expressing polynucleotides |
US7470675B2 (en) | 1997-11-20 | 2008-12-30 | Vical Incorporated | Methods for treating cancer using interferon-ω-expressing polynucleotides |
US6682928B2 (en) | 1997-12-02 | 2004-01-27 | Medarex, Inc. | Cells expressing anti-Fc receptor binding components |
US7316812B2 (en) | 1997-12-02 | 2008-01-08 | Celldex Therapeutics, Inc. | Cells expressing anti-Fc receptor binding components |
WO2000006605A3 (en) * | 1998-07-28 | 2000-06-29 | Micromet Ges Fuer Biomedizinis | Heterominibodies |
WO2000006605A2 (en) * | 1998-07-28 | 2000-02-10 | Micromet Ag | Heterominibodies |
US9145450B2 (en) | 1998-10-23 | 2015-09-29 | Amgen Inc. | Thrombopoietic compounds |
US6660843B1 (en) | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
US7488590B2 (en) | 1998-10-23 | 2009-02-10 | Amgen Inc. | Modified peptides as therapeutic agents |
US9534032B2 (en) | 1998-10-23 | 2017-01-03 | Amgen Inc. | Thrombopoietic compounds |
EA005404B1 (en) * | 1998-10-23 | 2005-02-24 | Амген Инк. | Modified peptides as therapeutic agents |
US7169905B2 (en) | 1998-10-23 | 2007-01-30 | Amgen Inc. | Modified peptides as therapeutic agents |
WO2000024782A3 (en) * | 1998-10-23 | 2002-06-06 | Amgen Inc | Modified peptides, comprising an fc domain, as therapeutic agents |
US7189827B2 (en) | 1998-10-23 | 2007-03-13 | Amgen Inc. | Modified peptides as therapeutic agents |
US7166707B2 (en) | 1998-10-23 | 2007-01-23 | Amgen Inc. | Modified peptides as therapeutic agents |
US8343496B2 (en) | 1999-05-10 | 2013-01-01 | Immunomedics, Inc. | Anti-CD74 immunoconjugates and methods |
US8119101B2 (en) | 1999-05-10 | 2012-02-21 | The Ohio State University | Anti-CD74 immunoconjugates and methods of use |
US7829064B2 (en) | 1999-05-10 | 2010-11-09 | Immunomedics, Inc. | Anti-CD74 immunoconjugates and methods |
US8383081B2 (en) | 1999-05-10 | 2013-02-26 | Immunomedics, Inc. | Anti-CD74 immunoconjugates and methods of use |
US8846002B2 (en) | 1999-05-10 | 2014-09-30 | The Ohio State University | Anti-CD74 immunoconjugates and methods of use |
US8986699B2 (en) | 1999-05-10 | 2015-03-24 | Immunomedics, Inc. | Anti-CD74 immunoconjugates and methods of use |
US8367037B2 (en) | 1999-05-10 | 2013-02-05 | Immunomedics, Inc. | Anti-CD74 immunoconjugates and methods of use |
US8481003B2 (en) | 1999-05-10 | 2013-07-09 | Immunomedics, Inc. | Anti-CD74 immunoconjugates and methods |
US8722859B2 (en) | 2000-04-11 | 2014-05-13 | Genentech, Inc. | Multivalent antibodies and uses therefor |
US9493579B2 (en) | 2000-04-11 | 2016-11-15 | Genentech, Inc. | Multivalent antibodies and uses therefor |
EP2857516A1 (en) | 2000-04-11 | 2015-04-08 | Genentech, Inc. | Multivalent antibodies and uses therefor |
WO2001083525A2 (en) * | 2000-05-03 | 2001-11-08 | Amgen Inc. | Modified peptides, comprising an fc domain, as therapeutic agents |
WO2001083525A3 (en) * | 2000-05-03 | 2002-07-18 | Amgen Inc | Modified peptides, comprising an fc domain, as therapeutic agents |
US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
EP1361892A4 (en) * | 2001-01-17 | 2004-10-13 | Trubion Pharmaceuticals Inc | Binding domain-immunoglobulin fusion proteins |
AU2008200400B2 (en) * | 2001-01-17 | 2012-06-07 | Aptevo Research And Development Llc | Binding domain-immunoglobulin fusion proteins |
US9005612B2 (en) | 2001-01-17 | 2015-04-14 | Emergent Product Development Seattle, Llc | Binding domain-immunoglobulin fusion proteins |
US7829084B2 (en) | 2001-01-17 | 2010-11-09 | Trubion Pharmaceuticals, Inc. | Binding constructs and methods for use thereof |
US8853366B2 (en) | 2001-01-17 | 2014-10-07 | Emergent Product Development Seattle, Llc | Binding domain-immunoglobulin fusion proteins |
EP1361892A1 (en) * | 2001-01-17 | 2003-11-19 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
US7319139B2 (en) | 2001-01-29 | 2008-01-15 | Biogen Idec, Inc. | TAG-72 specific CH2 domain deleted antibodies |
WO2002096948A2 (en) * | 2001-01-29 | 2002-12-05 | Idec Pharmaceuticals Corporation | Engineered tetravalent antibodies and methods of use |
WO2002096948A3 (en) * | 2001-01-29 | 2003-08-07 | Idec Pharma Corp | Engineered tetravalent antibodies and methods of use |
WO2003002144A1 (en) * | 2001-06-26 | 2003-01-09 | Imclone Systems Incorporated | Bispecific antibodies that bind to vegf receptors |
WO2003011909A1 (en) * | 2001-07-31 | 2003-02-13 | University Of Southampton | Binding agents with differential activity |
US9770517B2 (en) | 2002-03-01 | 2017-09-26 | Immunomedics, Inc. | Anti-Trop-2 antibody-drug conjugates and uses thereof |
US7026326B2 (en) | 2002-05-21 | 2006-04-11 | Amgen Inc. | Substituted heterocyclic compounds and methods of use |
US7534427B2 (en) * | 2002-12-31 | 2009-05-19 | Immunomedics, Inc. | Immunotherapy of B cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins |
US7700097B2 (en) | 2003-06-27 | 2010-04-20 | Biogen Idec Ma Inc. | Purification and preferential synthesis of binding molecules |
WO2005000899A2 (en) | 2003-06-27 | 2005-01-06 | Biogen Idec Ma Inc. | Modified binding molecules comprising connecting peptides |
US8603473B2 (en) | 2003-06-27 | 2013-12-10 | Biogen Idec Ma Inc. | Modified binding molecules comprising connecting peptides |
US8188239B2 (en) | 2003-07-01 | 2012-05-29 | Immunomedics, Inc. | Multivalent carriers of bi-specific antibodies |
US7951921B2 (en) | 2003-07-01 | 2011-05-31 | Immunomedics, Inc. | Multivalent carriers of bi-specific antibodies |
US7754209B2 (en) | 2003-07-26 | 2010-07-13 | Trubion Pharmaceuticals | Binding constructs and methods for use thereof |
US9550838B2 (en) | 2004-02-13 | 2017-01-24 | Ibc Pharmaceuticals, Inc. | Dock-and-lock (DNL) complexes for therapeutic and diagnostic use |
US8883160B2 (en) | 2004-02-13 | 2014-11-11 | Ibc Pharmaceuticals, Inc. | Dock-and-lock (DNL) complexes for therapeutic and diagnostic use |
WO2006074399A2 (en) * | 2005-01-05 | 2006-07-13 | Biogen Idec Ma Inc. | Multispecific binding molecules comprising connecting peptides |
WO2006074399A3 (en) * | 2005-01-05 | 2006-12-07 | Biogen Idec Inc | Multispecific binding molecules comprising connecting peptides |
US8084026B2 (en) | 2005-01-05 | 2011-12-27 | Biogen Idec Ma Inc. | Multispecific binding molecules comprising connecting peptides |
US10988539B2 (en) | 2005-03-03 | 2021-04-27 | Immunomedics, Inc. | Combination therapy with anti-HLA-DR antibodies and kinase inhibitors in hematopoietic cancers |
US9737617B2 (en) | 2005-04-06 | 2017-08-22 | Ibc Pharmaceuticals, Inc. | Multiple signaling pathways induced by hexavalent, monospecific and bispecific antibodies for enhanced toxicity to B-cell lymphomas and other diseases |
US9359443B2 (en) | 2005-04-06 | 2016-06-07 | Ibc Pharmaceuticals, Inc. | Combination therapy with anti-CD74 and anti-CD20 antibodies provides enhanced toxicity to B-cell diseases |
US8906378B2 (en) | 2005-04-06 | 2014-12-09 | Ibc Pharmaceuticals, Inc. | Combination therapy with anti-CD74 antibodies provides enhanced toxicity to malignancies, autoimmune disease and other diseases |
US8871216B2 (en) | 2005-04-06 | 2014-10-28 | Ibc Pharmaceuticals, Inc. | Multiple signaling pathways induced by hexvalent, monospecific and bispecific antibodies for enhanced toxicity to B-cell lymphomas and other diseases |
WO2006116657A3 (en) * | 2005-04-26 | 2007-05-18 | Glycofi Inc | Single-chain antibody with cleavable linker |
US10143748B2 (en) | 2005-07-25 | 2018-12-04 | Aptevo Research And Development Llc | B-cell reduction using CD37-specific and CD20-specific binding molecules |
US10307481B2 (en) | 2005-07-25 | 2019-06-04 | Aptevo Research And Development Llc | CD37 immunotherapeutics and uses thereof |
US9114175B2 (en) | 2005-08-12 | 2015-08-25 | Amgen Inc. | Modified Fc molecules |
US11266744B2 (en) | 2005-08-12 | 2022-03-08 | Amgen Inc. | Modified Fc molecules |
US10188740B2 (en) | 2005-08-12 | 2019-01-29 | Amgen Inc. | Modified Fc molecules |
EP2500352A1 (en) * | 2005-08-19 | 2012-09-19 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
EP1928506A2 (en) * | 2005-08-19 | 2008-06-11 | Abbott Laboratories | Dual variable domain immunoglobin and uses thereof |
EP2500355A3 (en) * | 2005-08-19 | 2012-10-24 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
EP2500356A3 (en) * | 2005-08-19 | 2012-10-24 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
EP2500354A3 (en) * | 2005-08-19 | 2012-10-24 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
EP2500357A3 (en) * | 2005-08-19 | 2012-10-24 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
EP2520588A1 (en) * | 2005-08-19 | 2012-11-07 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
EP2500359A3 (en) * | 2005-08-19 | 2012-10-17 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
EP2495257A3 (en) * | 2005-08-19 | 2012-10-17 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
EP2500358A3 (en) * | 2005-08-19 | 2012-10-17 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
AU2006283532B2 (en) * | 2005-08-19 | 2012-04-26 | Abbvie Inc. | Dual variable domain immunoglobin and uses thereof |
EP1928506A4 (en) * | 2005-08-19 | 2009-10-21 | Abbott Lab | Dual variable domain immunoglobin and uses thereof |
EP2500353A3 (en) * | 2005-08-19 | 2012-10-10 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
US8258268B2 (en) | 2005-08-19 | 2012-09-04 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
WO2007062466A1 (en) * | 2005-11-29 | 2007-06-07 | The University Of Sydney | Demibodies: dimerisation-activated therapeutic agents |
US8623356B2 (en) | 2005-11-29 | 2014-01-07 | The University Of Sydney | Demibodies: dimerization-activated therapeutic agents |
US8409577B2 (en) | 2006-06-12 | 2013-04-02 | Emergent Product Development Seattle, Llc | Single chain multivalent binding proteins with effector function |
EP2056869A4 (en) * | 2006-08-18 | 2009-10-21 | Abbott Lab | Dual variable domain immunoglobulin and uses thereof |
EP2056869A2 (en) * | 2006-08-18 | 2009-05-13 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
JP2010532764A (en) * | 2007-07-06 | 2010-10-14 | トゥルビオン・ファーマシューティカルズ・インコーポレーテッド | Binding peptide having a specific binding domain located at the C-terminus |
EP2167130A2 (en) * | 2007-07-06 | 2010-03-31 | Trubion Pharmaceuticals, Inc. | Binding peptides having a c-terminally disposed specific binding domain |
WO2009018386A1 (en) * | 2007-07-31 | 2009-02-05 | Medimmune, Llc | Multispecific epitope binding proteins and uses thereof |
US9828438B2 (en) | 2007-09-26 | 2017-11-28 | Ucb Pharma S.A. | Dual specificity antibody fusions |
US8629246B2 (en) | 2007-09-26 | 2014-01-14 | Ucb Pharma S.A. | Dual specificity antibody fusions |
US9309327B2 (en) | 2007-09-26 | 2016-04-12 | Ucb Pharma S.A. | Dual specificity antibody fusions |
US11427650B2 (en) | 2007-09-26 | 2022-08-30 | UCB Biopharma SRL | Dual specificity antibody fusions |
US10100130B2 (en) | 2007-09-26 | 2018-10-16 | Ucb Biopharma Sprl | Dual specificity antibody fusions |
US11453727B2 (en) | 2007-10-15 | 2022-09-27 | Sanofi | Antibodies that bind IL-4 and/or IL-13 and their uses |
US9732162B2 (en) | 2007-10-15 | 2017-08-15 | Sanofi | Antibodies that bind IL-4 and/or IL-13 and their uses |
US9738728B2 (en) | 2007-10-15 | 2017-08-22 | Sanofi | Antibodies that bind IL-4 and/or IL-13 and their uses |
EP2050764A1 (en) * | 2007-10-15 | 2009-04-22 | sanofi-aventis | Novel polyvalent bispecific antibody format and uses thereof |
US10759871B2 (en) | 2007-10-15 | 2020-09-01 | Sanofi | Antibodies that bind IL-4 and/or IL-13 and their uses |
US9266967B2 (en) | 2007-12-21 | 2016-02-23 | Hoffmann-La Roche, Inc. | Bivalent, bispecific antibodies |
US10138293B2 (en) | 2007-12-21 | 2018-11-27 | Hoffmann-La Roche, Inc. | Bivalent, bispecific antibodies |
US10927163B2 (en) | 2007-12-21 | 2021-02-23 | Hoffmann-La Roche, Inc. | Bivalent, bispecific antibodies |
US8333966B2 (en) | 2008-04-11 | 2012-12-18 | Emergent Product Development Seattle, Llc | CD37 immunotherapeutics and uses thereof |
US9101609B2 (en) | 2008-04-11 | 2015-08-11 | Emergent Product Development Seattle, Llc | CD37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof |
US9758594B2 (en) | 2008-04-25 | 2017-09-12 | Kyowa Hakko Kirin Co., Ltd. | Stable multivalent antibody |
EP2281845A4 (en) * | 2008-04-25 | 2015-11-04 | Kyowa Hakko Kirin Co Ltd | Stable polyvalent antibody |
US9029508B2 (en) | 2008-04-29 | 2015-05-12 | Abbvie Inc. | Dual variable domain immunoglobulins and uses thereof |
US9109026B2 (en) | 2008-06-03 | 2015-08-18 | Abbvie, Inc. | Dual variable domain immunoglobulins and uses thereof |
US9035027B2 (en) | 2008-06-03 | 2015-05-19 | Abbvie Inc. | Dual variable domain immunoglobulins and uses thereof |
US8822645B2 (en) | 2008-07-08 | 2014-09-02 | Abbvie Inc. | Prostaglandin E2 dual variable domain immunoglobulins and uses thereof |
US10407513B2 (en) | 2008-09-26 | 2019-09-10 | Ucb Biopharma Sprl | Biological products |
EP2781526A1 (en) | 2008-10-08 | 2014-09-24 | F. Hoffmann-La Roche AG | Bispecific anti-VEGF/anti-ANG-2 antibodies |
US8268314B2 (en) | 2008-10-08 | 2012-09-18 | Hoffmann-La Roche Inc. | Bispecific anti-VEGF/anti-ANG-2 antibodies |
US9708396B2 (en) | 2008-10-08 | 2017-07-18 | Hoffmann-La Roche Inc. | Bispecific anti-VEGF/anti-ANG-2 antibodies |
EP2792687A1 (en) | 2008-10-08 | 2014-10-22 | F. Hoffmann-La Roche AG | Bispecific anti-VEGF/anti-ANG-2 antibodies |
US8703130B2 (en) | 2008-10-08 | 2014-04-22 | Hoffmann-La Roche, Inc. | Bispecific anti-VEGF/anti-ANG-2 antibodies |
WO2010040508A1 (en) | 2008-10-08 | 2010-04-15 | F. Hoffmann-La Roche Ag | Bispecific anti-vegf/anti-ang-2 antibodies |
US9220791B2 (en) | 2008-11-06 | 2015-12-29 | University Of Washington | Bispecific intracellular delivery vehicles |
WO2010085590A1 (en) | 2009-01-23 | 2010-07-29 | Biosynexus Incorporated | Opsonic and protective antibodies specific for lipoteichoic acid gram positive bacteria |
RU2598248C2 (en) * | 2009-04-02 | 2016-09-20 | Роше Гликарт Аг | Polyspecific antibodies containing antibody of full length and one-chain fragments fab |
WO2010112194A1 (en) | 2009-04-02 | 2010-10-07 | F. Hoffmann-La Roche Ag | Antigen-binding polypeptides and multispecific antibodies comprising them |
CN102369215A (en) * | 2009-04-02 | 2012-03-07 | 罗切格利卡特公司 | Multispecific antibodies comprising full length antibodies and single chain fab fragments |
CN102369215B (en) * | 2009-04-02 | 2015-01-21 | 罗切格利卡特公司 | Multispecific antibodies comprising full length antibodies and single chain fab fragments |
WO2010112193A1 (en) | 2009-04-02 | 2010-10-07 | Roche Glycart Ag | Multispecific antibodies comprising full length antibodies and single chain fab fragments |
US9382323B2 (en) | 2009-04-02 | 2016-07-05 | Roche Glycart Ag | Multispecific antibodies comprising full length antibodies and single chain fab fragments |
WO2010115553A1 (en) | 2009-04-07 | 2010-10-14 | Roche Glycart Ag | Bispecific anti-erbb-2/anti-c-met antibodies |
WO2010115551A1 (en) | 2009-04-07 | 2010-10-14 | Roche Glycart Ag | Bispecific anti-erbb-1/anti-c-met antibodies |
WO2010115589A1 (en) | 2009-04-07 | 2010-10-14 | Roche Glycart Ag | Trivalent, bispecific antibodies |
US9890204B2 (en) | 2009-04-07 | 2018-02-13 | Hoffmann-La Roche Inc. | Trivalent, bispecific antibodies |
WO2010115552A1 (en) | 2009-04-07 | 2010-10-14 | Roche Glycart Ag | Bispecific anti-erbb-3/anti-c-met antibodies |
US8796424B2 (en) | 2009-05-27 | 2014-08-05 | Hoffmann-La Roche Inc. | Tri- or tetraspecific antibodies |
US9676845B2 (en) | 2009-06-16 | 2017-06-13 | Hoffmann-La Roche, Inc. | Bispecific antigen binding proteins |
US11673945B2 (en) | 2009-06-16 | 2023-06-13 | Hoffmann-La Roche Inc. | Bispecific antigen binding proteins |
US10640555B2 (en) | 2009-06-16 | 2020-05-05 | Hoffmann-La Roche Inc. | Bispecific antigen binding proteins |
US8586714B2 (en) | 2009-09-01 | 2013-11-19 | Abbvie, Inc. | Dual variable domain immunoglobulins and uses thereof |
WO2011028952A1 (en) * | 2009-09-02 | 2011-03-10 | Xencor, Inc. | Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens |
US9493578B2 (en) | 2009-09-02 | 2016-11-15 | Xencor, Inc. | Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens |
US9994646B2 (en) | 2009-09-16 | 2018-06-12 | Genentech, Inc. | Coiled coil and/or tether containing protein complexes and uses thereof |
US8716450B2 (en) | 2009-10-15 | 2014-05-06 | Abbvie Inc. | Dual variable domain immunoglobulins and uses thereof |
US8722855B2 (en) | 2009-10-28 | 2014-05-13 | Abbvie Inc. | Dual variable domain immunoglobulins and uses thereof |
US8945552B2 (en) | 2010-03-26 | 2015-02-03 | Hoffmann-La Roche Inc. | Bispecific, bivalent anti-VEGF/anti-ANG-2 antibodies |
WO2011117330A1 (en) | 2010-03-26 | 2011-09-29 | Roche Glycart Ag | Bispecific antibodies |
WO2011117329A1 (en) | 2010-03-26 | 2011-09-29 | F. Hoffmann-La Roche Ag | Bispecific, bivalent anti-vegf/anti-ang-2 antibodies |
US10106600B2 (en) | 2010-03-26 | 2018-10-23 | Roche Glycart Ag | Bispecific antibodies |
US8735546B2 (en) | 2010-08-03 | 2014-05-27 | Abbvie Inc. | Dual variable domain immunoglobulins and uses thereof |
US9493560B2 (en) | 2010-08-03 | 2016-11-15 | Abbvie Inc. | Dual variable domain immunoglobulins and uses thereof |
US9879095B2 (en) | 2010-08-24 | 2018-01-30 | Hoffman-La Roche Inc. | Bispecific antibodies comprising a disulfide stabilized-Fv fragment |
US9046513B2 (en) | 2010-08-26 | 2015-06-02 | Abbvie Inc. | Dual variable domain immunoglobulins and uses thereof |
US11618790B2 (en) | 2010-12-23 | 2023-04-04 | Hoffmann-La Roche Inc. | Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery |
US10611825B2 (en) | 2011-02-28 | 2020-04-07 | Hoffmann La-Roche Inc. | Monovalent antigen binding proteins |
US10793621B2 (en) | 2011-02-28 | 2020-10-06 | Hoffmann-La Roche Inc. | Nucleic acid encoding dual Fc antigen binding proteins |
US9982036B2 (en) | 2011-02-28 | 2018-05-29 | Hoffmann-La Roche Inc. | Dual FC antigen binding proteins |
US9757458B2 (en) | 2011-12-05 | 2017-09-12 | Immunomedics, Inc. | Crosslinking of CD22 by epratuzumab triggers BCR signaling and caspase-dependent apoptosis in hematopoietic cancer cells |
US9663576B2 (en) | 2011-12-05 | 2017-05-30 | Immunomedics, Inc. | Therapeutic use of anti-CD22 antibodies for inducing trogocytosis |
US9963507B2 (en) | 2011-12-05 | 2018-05-08 | Immunomedics, Inc. | Therapeutic use of anti-CD22 antibodies for inducing trogocytosis |
US9192664B2 (en) | 2011-12-05 | 2015-11-24 | Immunomedics, Inc. | Therapeutic use of anti-CD22 antibodies for inducing trogocytosis |
US9475883B2 (en) | 2011-12-05 | 2016-10-25 | Immunomedics, Inc. | Therapeutic use of anti-CD22 antibodies for inducing trogocytosis |
WO2013101909A1 (en) * | 2011-12-27 | 2013-07-04 | Development Center For Biotechnology | Light chain-bridged bispecific antibody |
US9120870B2 (en) | 2011-12-30 | 2015-09-01 | Abbvie Inc. | Dual specific binding proteins directed against IL-13 and IL-17 |
US9688758B2 (en) | 2012-02-10 | 2017-06-27 | Genentech, Inc. | Single-chain antibodies and other heteromultimers |
US9714292B2 (en) | 2012-04-05 | 2017-07-25 | Hoffmann-La Roche Inc. | Bispecific antibodies against human TWEAK and human IL17 and uses thereof |
WO2013150043A1 (en) | 2012-04-05 | 2013-10-10 | F. Hoffmann-La Roche Ag | Bispecific antibodies against human tweak and human il17 and uses thereof |
KR101673735B1 (en) | 2012-04-20 | 2016-11-07 | 일라이 릴리 앤드 캄파니 | Anti-baff-anti-il-17 bispecific antibodies |
US9359448B2 (en) | 2012-04-20 | 2016-06-07 | Eli Lilly And Company | Anti-BAFF-anti-IL-17 bispecific antibodies |
EP3192809A1 (en) | 2012-04-20 | 2017-07-19 | Eli Lilly and Company | Anti-baff-anti-il-17 bispecific antibodies |
WO2013158577A1 (en) | 2012-04-20 | 2013-10-24 | Eli Lilly And Company | Anti-baff-anti-il-17 bispecific antibodies |
KR20140135830A (en) * | 2012-04-20 | 2014-11-26 | 일라이 릴리 앤드 캄파니 | Anti-baff-anti-il-17 bispecific antibodies |
US11421022B2 (en) | 2012-06-27 | 2022-08-23 | Hoffmann-La Roche Inc. | Method for making antibody Fc-region conjugates comprising at least one binding entity that specifically binds to a target and uses thereof |
US10106612B2 (en) | 2012-06-27 | 2018-10-23 | Hoffmann-La Roche Inc. | Method for selection and production of tailor-made highly selective and multi-specific targeting entities containing at least two different binding entities and uses thereof |
US11407836B2 (en) | 2012-06-27 | 2022-08-09 | Hoffmann-La Roche Inc. | Method for selection and production of tailor-made highly selective and multi-specific targeting entities containing at least two different binding entities and uses thereof |
WO2014006124A1 (en) | 2012-07-04 | 2014-01-09 | F. Hoffmann-La Roche Ag | Covalently linked antigen-antibody conjugates |
US9925272B2 (en) | 2012-07-04 | 2018-03-27 | Hoffmann-La Roche Inc. | Anti-theophylline antibodies and methods of use |
US9765153B2 (en) | 2012-07-04 | 2017-09-19 | Hoffmann-La Roche Inc. | Anti-biotin antibodies and methods of use |
US10517945B2 (en) | 2012-07-04 | 2019-12-31 | Hoffman-La Roche Inc. | Covalently linked antigen-antibody conjugates |
US9695233B2 (en) | 2012-07-13 | 2017-07-04 | Roche Glycart Ag | Bispecific anti-VEGF/anti-ANG-2 antibodies and their use in the treatment of ocular vascular diseases |
US10683345B2 (en) | 2012-07-13 | 2020-06-16 | Roche Glycart Ag | Bispecific anti-VEGF/anti-ANG-2 antibodies and their use in the treatment of ocular vascular diseases |
US9944720B2 (en) | 2012-11-01 | 2018-04-17 | Abbvie Inc. | Anti-DLL4/VEGF dual variable domain immunoglobulin and uses thereof |
US9163093B2 (en) | 2012-11-01 | 2015-10-20 | Abbvie Inc. | Anti-DLL4/VEGF dual variable domain immunoglobulin and uses thereof |
US9045551B2 (en) | 2012-11-01 | 2015-06-02 | Abbvie Inc. | Anti-DLL4/VEGF dual variable domain immunoglobulin and uses thereof |
US9931417B2 (en) | 2012-12-13 | 2018-04-03 | Immunomedics, Inc. | Antibody-SN-38 immunoconjugates with a CL2A linker |
US9493573B2 (en) | 2012-12-13 | 2016-11-15 | Immunomedics, Inc. | Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity |
US11116846B2 (en) | 2012-12-13 | 2021-09-14 | Immunomedics, Inc. | Antibody-drug conjugates and uses thereof |
US11052156B2 (en) | 2012-12-13 | 2021-07-06 | Immunomedics, Inc. | Antibody-drug conjugates and uses thereof |
US9375489B2 (en) | 2012-12-13 | 2016-06-28 | Immunomedics, Inc. | Antibody-SN-38 immunoconjugates with a CL2A linker |
US9522959B2 (en) | 2012-12-13 | 2016-12-20 | Immunomedics, Inc. | Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity |
US9226973B2 (en) | 2012-12-13 | 2016-01-05 | Immunomedics, Inc. | Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity |
US9499631B2 (en) | 2012-12-13 | 2016-11-22 | Immunomedics, Inc. | Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity |
US9493574B2 (en) | 2012-12-13 | 2016-11-15 | Immunomedics, Inc. | Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity |
US10413539B2 (en) | 2012-12-13 | 2019-09-17 | Immunomedics, Inc. | Therapy for metastatic urothelial cancer with the antibody-drug conjugate, sacituzumab govitecan (IMMU-132) |
US10653793B2 (en) | 2012-12-13 | 2020-05-19 | Immunomedics, Inc. | Antibody-drug conjugates and uses thereof |
US9492566B2 (en) | 2012-12-13 | 2016-11-15 | Immunomedics, Inc. | Antibody-drug conjugates and uses thereof |
US11541047B2 (en) | 2012-12-13 | 2023-01-03 | Immunomedics, Inc. | Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity |
US10682347B2 (en) | 2012-12-13 | 2020-06-16 | Immunomedics, Inc. | Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity |
US10206918B2 (en) | 2012-12-13 | 2019-02-19 | Immunomedics, Inc. | Efficacy of anti-HLA-DR antiboddy drug conjugate IMMU-140 (hL243-CL2A-SN-38) in HLA-DR positive cancers |
US10709701B2 (en) | 2012-12-13 | 2020-07-14 | Immunomedics, Inc. | Efficacy of anti-HLA-DR antibody drug conjugate IMMU-140 (hL243-CL2A-SN-38) in HLA-DR positive cancers |
US9629926B2 (en) | 2012-12-13 | 2017-04-25 | Immunomedics, Inc. | Antibody-SN-38 immunoconjugates with a CL2A linker |
US10744129B2 (en) | 2012-12-13 | 2020-08-18 | Immunomedics, Inc. | Therapy of small-cell lung cancer (SCLC) with a topoisomerase-I inhibiting antibody-drug conjugate (ADC) targeting Trop-2 |
US9475884B2 (en) | 2012-12-13 | 2016-10-25 | Immunomedics, Inc. | Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity |
US10034950B2 (en) | 2012-12-13 | 2018-07-31 | Immunomedics, Inc. | Antibody-SN-38 immunoconjugates with a CL2A linker |
US10143756B2 (en) | 2012-12-13 | 2018-12-04 | Immunomedics, Inc. | Antibody-SN-38 immunoconjugates with a CL2A linker |
US11052081B2 (en) | 2012-12-13 | 2021-07-06 | Immunomedics, Inc. | Therapy for metastatic urothelial cancer with the antibody-drug conjugate, sacituzumab govitecan (IMMU-132) |
US10137196B2 (en) | 2012-12-13 | 2018-11-27 | Immunomedics, Inc. | Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity |
US10849986B2 (en) | 2012-12-13 | 2020-12-01 | Immunomedics, Inc. | Antibody-drug conjugates and uses thereof |
US9107960B2 (en) | 2012-12-13 | 2015-08-18 | Immunimedics, Inc. | Antibody-SN-38 immunoconjugates with a CL2A linker |
US9855344B2 (en) | 2012-12-13 | 2018-01-02 | Immunomedics, Inc. | Antibody-SN-38 immunoconjugates with a CL2A linker |
US9028833B2 (en) | 2012-12-13 | 2015-05-12 | Immunomedics, Inc. | Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity |
US10130718B2 (en) | 2012-12-13 | 2018-11-20 | Immunomedics, Inc. | Antibody-drug conjugates and uses thereof |
US9481732B2 (en) | 2012-12-13 | 2016-11-01 | Immunomedics, Inc. | Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity |
US10130626B2 (en) | 2012-12-13 | 2018-11-20 | Immunomedics, Inc. | Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity |
US10751420B2 (en) | 2012-12-13 | 2020-08-25 | Immunomedics, Inc. | Antibody-SN-38 immunoconjugates with a CL2A linker |
US9458242B2 (en) | 2012-12-13 | 2016-10-04 | Immunomedics, Inc. | Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity |
CN105283467A (en) * | 2013-03-08 | 2016-01-27 | 伊莱利利公司 | Anti-TNF-anti-IL-17 bispecific antibodies |
JP2016510743A (en) * | 2013-03-08 | 2016-04-11 | イーライ リリー アンド カンパニー | Anti-TNF-anti-IL-17 bispecific antibody |
US9416182B2 (en) | 2013-03-08 | 2016-08-16 | Eli Lilly And Company | Anti-TNF-anti-IL-17 bispecific antibodies |
WO2014137961A1 (en) | 2013-03-08 | 2014-09-12 | Eli Lilly And Company | Anti-tnf-anti-il-17 bispecific antibodies |
US8987418B2 (en) | 2013-03-15 | 2015-03-24 | Abbvie Inc. | Dual specific binding proteins directed against IL-1β and/or IL-17 |
US9062108B2 (en) | 2013-03-15 | 2015-06-23 | Abbvie Inc. | Dual specific binding proteins directed against IL-1 and/or IL-17 |
US11253606B2 (en) | 2013-07-23 | 2022-02-22 | Immunomedics, Inc. | Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, Bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer |
US9707302B2 (en) | 2013-07-23 | 2017-07-18 | Immunomedics, Inc. | Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer |
US20150044216A1 (en) * | 2013-08-06 | 2015-02-12 | Bio-Thera Solutions, Ltd. | Bispecific antibodies |
US9567403B2 (en) | 2013-08-06 | 2017-02-14 | Bio-Thera Solutions, Ltd. | Bispecific antibodies which bind EGFR and VEGF |
US10323099B2 (en) | 2013-10-11 | 2019-06-18 | Hoffmann-La Roche Inc. | Multispecific domain exchanged common variable light chain antibodies |
US10465000B2 (en) | 2013-12-20 | 2019-11-05 | Hoffmann-La Roche Inc. | Humanized anti-Tau(pS422) antibodies and methods of use |
WO2015100104A1 (en) | 2013-12-23 | 2015-07-02 | Eli Lilly And Company | Multifunctional antibodies binding to egfr and met |
US9328173B2 (en) | 2013-12-23 | 2016-05-03 | Eli Lilly And Company | Multifunctional antibodies binding to EGFR and MET |
US10407511B2 (en) | 2014-01-03 | 2019-09-10 | Hoffmann-La Roche Inc. | Covalently linked helicar-anti-helicar antibody conjugates and uses thereof |
US10519249B2 (en) | 2014-01-03 | 2019-12-31 | Hoffmann-La Roche Inc. | Covalently linked polypeptide toxin-antibody conjugates |
WO2015101589A1 (en) | 2014-01-03 | 2015-07-09 | F. Hoffmann-La Roche Ag | Covalently linked polypeptide toxin-antibody conjugates |
WO2015101587A1 (en) | 2014-01-03 | 2015-07-09 | F. Hoffmann-La Roche Ag | Covalently linked helicar-anti-helicar antibody conjugates and uses thereof |
US10561737B2 (en) | 2014-01-03 | 2020-02-18 | Hoffmann-La Roche Inc. | Bispecific anti-hapten/anti-blood brain barrier receptor antibodies, complexes thereof and their use as blood brain barrier shuttles |
WO2015101586A1 (en) | 2014-01-03 | 2015-07-09 | F. Hoffmann-La Roche Ag | Bispecific anti-hapten/anti-blood brain barrier receptor antibodies, complexes thereof and their use as blood brain barrier shuttles |
EP3514179A1 (en) | 2014-01-24 | 2019-07-24 | Dana-Farber Cancer Institute, Inc. | Antibody molecules to pd-1 and uses thereof |
EP4324518A2 (en) | 2014-01-31 | 2024-02-21 | Novartis AG | Antibody molecules to tim-3 and uses thereof |
WO2015138920A1 (en) | 2014-03-14 | 2015-09-17 | Novartis Ag | Antibody molecules to lag-3 and uses thereof |
EP3660050A1 (en) | 2014-03-14 | 2020-06-03 | Novartis AG | Antibody molecules to lag-3 and uses thereof |
WO2015142675A2 (en) | 2014-03-15 | 2015-09-24 | Novartis Ag | Treatment of cancer using chimeric antigen receptor |
WO2015153765A1 (en) | 2014-04-01 | 2015-10-08 | Adimab, Llc | Multispecific antibody analogs comprising a common light chain, and methods of their preparation and use |
EP4050026A1 (en) | 2014-04-01 | 2022-08-31 | Adimab, LLC | Method of obtaining or identifying one or more common light chains for use in preparing a multispecific antibody |
EP3825326A1 (en) | 2014-04-01 | 2021-05-26 | Adimab, LLC | Multispecific antibody analogs comprising a common light chain, and methods of their preparation and use |
CN104311670A (en) * | 2014-04-23 | 2015-01-28 | 哈尔滨博翱生物医药技术开发有限公司 | Fused polypeptide for IL-17 and TNF[alpha], and application thereof |
CN104311670B (en) * | 2014-04-23 | 2017-05-17 | 哈尔滨博翱生物医药技术开发有限公司 | Fused polypeptide for IL-17 and TNF[alpha], and application thereof |
US10251952B2 (en) | 2014-06-26 | 2019-04-09 | Hoffmann-La Roche Inc. | Humanized anti-tau(pS422) antibody brain shuttles and use thereof |
US10973920B2 (en) | 2014-06-30 | 2021-04-13 | Glykos Finland Oy | Saccharide derivative of a toxic payload and antibody conjugates thereof |
US9884921B2 (en) | 2014-07-01 | 2018-02-06 | Pfizer Inc. | Bispecific heterodimeric diabodies and uses thereof |
WO2016014553A1 (en) | 2014-07-21 | 2016-01-28 | Novartis Ag | Sortase synthesized chimeric antigen receptors |
WO2016014530A1 (en) | 2014-07-21 | 2016-01-28 | Novartis Ag | Combinations of low, immune enhancing. doses of mtor inhibitors and cars |
EP3722316A1 (en) | 2014-07-21 | 2020-10-14 | Novartis AG | Treatment of cancer using a cd33 chimeric antigen receptor |
WO2016014565A2 (en) | 2014-07-21 | 2016-01-28 | Novartis Ag | Treatment of cancer using humanized anti-bcma chimeric antigen receptor |
EP3660042A1 (en) | 2014-07-31 | 2020-06-03 | Novartis AG | Subset-optimized chimeric antigen receptor-containing t-cells |
EP4205749A1 (en) | 2014-07-31 | 2023-07-05 | Novartis AG | Subset-optimized chimeric antigen receptor-containing cells |
WO2016025880A1 (en) | 2014-08-14 | 2016-02-18 | Novartis Ag | Treatment of cancer using gfr alpha-4 chimeric antigen receptor |
EP3712171A1 (en) | 2014-08-19 | 2020-09-23 | Novartis AG | Treatment of cancer using a cd123 chimeric antigen receptor |
WO2016044605A1 (en) | 2014-09-17 | 2016-03-24 | Beatty, Gregory | Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy |
EP3967709A1 (en) | 2014-09-17 | 2022-03-16 | Novartis AG | Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy |
WO2016061142A1 (en) | 2014-10-14 | 2016-04-21 | Novartis Ag | Antibody molecules to pd-l1 and uses thereof |
EP4245376A2 (en) | 2014-10-14 | 2023-09-20 | Novartis AG | Antibody molecules to pd-l1 and uses thereof |
US9718884B2 (en) | 2014-11-05 | 2017-08-01 | Eli Lilly And Company | Anti-TNF-/anti-IL-23 bispecific antibodies |
US10633457B2 (en) | 2014-12-03 | 2020-04-28 | Hoffmann-La Roche Inc. | Multispecific antibodies |
WO2016090034A2 (en) | 2014-12-03 | 2016-06-09 | Novartis Ag | Methods for b cell preconditioning in car therapy |
US10093733B2 (en) | 2014-12-11 | 2018-10-09 | Abbvie Inc. | LRP-8 binding dual variable domain immunoglobulin proteins |
WO2016160476A1 (en) | 2015-04-03 | 2016-10-06 | Eli Lilly And Company | Anti-cd20- / anti-baff bispecific antibodies |
US9951146B2 (en) | 2015-04-03 | 2018-04-24 | Eli Lilly And Company | Anti-CD20− / anti-BAFF bispecific antibodies |
WO2016164731A2 (en) | 2015-04-08 | 2016-10-13 | Novartis Ag | Cd20 therapies, cd22 therapies, and combination therapies with a cd19 chimeric antigen receptor (car) - expressing cell |
EP4056588A1 (en) | 2015-04-08 | 2022-09-14 | Novartis AG | Cd20 therapies, cd22 therapies, and combination therapies with a cd19 chimeric antigen receptor (car)- expressing cell |
US9797907B2 (en) | 2015-04-22 | 2017-10-24 | Immunomedics, Inc. | Isolation, detection, diagnosis and/or characterization of circulating Trop-2-positive cancer cells |
US10436788B2 (en) | 2015-04-22 | 2019-10-08 | Immunomedics, Inc. | Isolation, detection, diagnosis and/or characterization of circulating Trop-2-positive cancer cells |
WO2016172583A1 (en) | 2015-04-23 | 2016-10-27 | Novartis Ag | Treatment of cancer using chimeric antigen receptor and protein kinase a blocker |
US9840554B2 (en) | 2015-06-15 | 2017-12-12 | Abbvie Inc. | Antibodies against platelet-derived growth factor (PDGF) |
US10822402B2 (en) | 2015-06-24 | 2020-11-03 | Hoffmann-La Roche Inc. | Humanized anti-tau(pS422) antibodies and methods of use |
US11439620B2 (en) | 2015-06-25 | 2022-09-13 | Immunomedics, Inc. | Synergistic effect of anti-trop-2 antibody-drug conjugate in combination therapy for triple-negative breast cancer when used with microtubule inhibitors or PARP inhibitors |
US10058621B2 (en) | 2015-06-25 | 2018-08-28 | Immunomedics, Inc. | Combination therapy with anti-HLA-DR antibodies and kinase inhibitors in hematopoietic cancers |
US10195175B2 (en) | 2015-06-25 | 2019-02-05 | Immunomedics, Inc. | Synergistic effect of anti-Trop-2 antibody-drug conjugate in combination therapy for triple-negative breast cancer when used with microtubule inhibitors or PARP inhibitors |
WO2017019894A1 (en) | 2015-07-29 | 2017-02-02 | Novartis Ag | Combination therapies comprising antibody molecules to lag-3 |
WO2017019897A1 (en) | 2015-07-29 | 2017-02-02 | Novartis Ag | Combination therapies comprising antibody molecules to tim-3 |
EP3964528A1 (en) | 2015-07-29 | 2022-03-09 | Novartis AG | Combination therapies comprising antibody molecules to lag-3 |
EP3878465A1 (en) | 2015-07-29 | 2021-09-15 | Novartis AG | Combination therapies comprising antibody molecules to tim-3 |
US11352426B2 (en) | 2015-09-21 | 2022-06-07 | Aptevo Research And Development Llc | CD3 binding polypeptides |
WO2017106810A2 (en) | 2015-12-17 | 2017-06-22 | Novartis Ag | Combination of c-met inhibitor with antibody molecule to pd-1 and uses thereof |
WO2017106656A1 (en) | 2015-12-17 | 2017-06-22 | Novartis Ag | Antibody molecules to pd-1 and uses thereof |
WO2017125897A1 (en) | 2016-01-21 | 2017-07-27 | Novartis Ag | Multispecific molecules targeting cll-1 |
EP3851457A1 (en) | 2016-01-21 | 2021-07-21 | Novartis AG | Multispecific molecules targeting cll-1 |
US10954305B2 (en) | 2016-02-10 | 2021-03-23 | Immunomedics, Inc. | Combination of ABCG2 inhibitors with sacituzumab govitecan (IMMU-132) overcomes resistance to SN-38 in Trop-2 expressing cancers |
WO2017149515A1 (en) | 2016-03-04 | 2017-09-08 | Novartis Ag | Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore |
WO2017165464A1 (en) | 2016-03-21 | 2017-09-28 | Elstar Therapeutics, Inc. | Multispecific and multifunctional molecules and uses thereof |
US11291721B2 (en) | 2016-03-21 | 2022-04-05 | Marengo Therapeutics, Inc. | Multispecific and multifunctional molecules and uses thereof |
WO2017165683A1 (en) | 2016-03-23 | 2017-09-28 | Novartis Ag | Cell secreted minibodies and uses thereof |
EP4219721A2 (en) | 2016-04-15 | 2023-08-02 | Novartis AG | Compositions and methods for selective protein expression |
WO2017181119A2 (en) | 2016-04-15 | 2017-10-19 | Novartis Ag | Compositions and methods for selective protein expression |
US10266605B2 (en) | 2016-04-27 | 2019-04-23 | Immunomedics, Inc. | Efficacy of anti-trop-2-SN-38 antibody drug conjugates for therapy of tumors relapsed/refractory to checkpoint inhibitors |
US11192955B2 (en) | 2016-04-27 | 2021-12-07 | Immunomedics, Inc. | Efficacy of anti-Trop-2-SN-38 antibody drug conjugates for therapy of tumors relapsed/refractory to checkpoint inhibitors |
WO2017210617A2 (en) | 2016-06-02 | 2017-12-07 | Porter, David, L. | Therapeutic regimens for chimeric antigen receptor (car)- expressing cells |
WO2018013918A2 (en) | 2016-07-15 | 2018-01-18 | Novartis Ag | Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitor |
WO2018023025A1 (en) | 2016-07-28 | 2018-02-01 | Novartis Ag | Combination therapies of chimeric antigen receptors adn pd-1 inhibitors |
WO2018026819A2 (en) | 2016-08-01 | 2018-02-08 | Novartis Ag | Treatment of cancer using a chimeric antigen receptor in combination with an inhibitor of a pro-m2 macrophage molecule |
WO2018067992A1 (en) | 2016-10-07 | 2018-04-12 | Novartis Ag | Chimeric antigen receptors for the treatment of cancer |
WO2018140725A1 (en) | 2017-01-26 | 2018-08-02 | Novartis Ag | Cd28 compositions and methods for chimeric antigen receptor therapy |
EP4043485A1 (en) | 2017-01-26 | 2022-08-17 | Novartis AG | Cd28 compositions and methods for chimeric antigen receptor therapy |
WO2018151820A1 (en) | 2017-02-16 | 2018-08-23 | Elstar Therapeutics, Inc. | Multifunctional molecules comprising a trimeric ligand and uses thereof |
WO2018160731A1 (en) | 2017-02-28 | 2018-09-07 | Novartis Ag | Shp inhibitor compositions and uses for chimeric antigen receptor therapy |
US10918734B2 (en) | 2017-03-27 | 2021-02-16 | Immunomedics, Inc. | Treatment of high Trop-2 expressing triple negative breast cancer (TNBC) with sacituzumab govitecan (IMMU-132) overcomes homologous recombination repair (HRR) rescue mediated by Rad51 |
US10799597B2 (en) | 2017-04-03 | 2020-10-13 | Immunomedics, Inc. | Subcutaneous administration of antibody-drug conjugates for cancer therapy |
WO2018201051A1 (en) | 2017-04-28 | 2018-11-01 | Novartis Ag | Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor |
WO2018201056A1 (en) | 2017-04-28 | 2018-11-01 | Novartis Ag | Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor |
WO2018222901A1 (en) | 2017-05-31 | 2018-12-06 | Elstar Therapeutics, Inc. | Multispecific molecules that bind to myeloproliferative leukemia (mpl) protein and uses thereof |
WO2018237157A1 (en) | 2017-06-22 | 2018-12-27 | Novartis Ag | Antibody molecules to cd73 and uses thereof |
WO2019006007A1 (en) | 2017-06-27 | 2019-01-03 | Novartis Ag | Dosage regimens for anti-tim-3 antibodies and uses thereof |
US11752207B2 (en) | 2017-07-11 | 2023-09-12 | Compass Therapeutics Llc | Agonist antibodies that bind human CD137 and uses thereof |
WO2019018730A1 (en) | 2017-07-20 | 2019-01-24 | Novartis Ag | Dosage regimens of anti-lag-3 antibodies and uses thereof |
WO2019035938A1 (en) | 2017-08-16 | 2019-02-21 | Elstar Therapeutics, Inc. | Multispecific molecules that bind to bcma and uses thereof |
US11718679B2 (en) | 2017-10-31 | 2023-08-08 | Compass Therapeutics Llc | CD137 antibodies and PD-1 antagonists and uses thereof |
WO2019089798A1 (en) | 2017-10-31 | 2019-05-09 | Novartis Ag | Anti-car compositions and methods |
WO2019099838A1 (en) | 2017-11-16 | 2019-05-23 | Novartis Ag | Combination therapies |
US11851497B2 (en) | 2017-11-20 | 2023-12-26 | Compass Therapeutics Llc | CD137 antibodies and tumor antigen-targeting antibodies and uses thereof |
WO2019152660A1 (en) | 2018-01-31 | 2019-08-08 | Novartis Ag | Combination therapy using a chimeric antigen receptor |
WO2019178364A2 (en) | 2018-03-14 | 2019-09-19 | Elstar Therapeutics, Inc. | Multifunctional molecules and uses thereof |
WO2019178362A1 (en) | 2018-03-14 | 2019-09-19 | Elstar Therapeutics, Inc. | Multifunctional molecules that bind to calreticulin and uses thereof |
WO2019200229A1 (en) | 2018-04-13 | 2019-10-17 | Novartis Ag | Dosage regimens for anti-pd-l1 antibodies and uses thereof |
WO2019210153A1 (en) | 2018-04-27 | 2019-10-31 | Novartis Ag | Car t cell therapies with enhanced efficacy |
WO2019226617A1 (en) | 2018-05-21 | 2019-11-28 | Compass Therapeutics Llc | Compositions and methods for enhancing the killing of target cells by nk cells |
WO2019226658A1 (en) | 2018-05-21 | 2019-11-28 | Compass Therapeutics Llc | Multispecific antigen-binding compositions and methods of use |
WO2019227003A1 (en) | 2018-05-25 | 2019-11-28 | Novartis Ag | Combination therapy with chimeric antigen receptor (car) therapies |
WO2019232244A2 (en) | 2018-05-31 | 2019-12-05 | Novartis Ag | Antibody molecules to cd73 and uses thereof |
US11332541B2 (en) | 2018-06-09 | 2022-05-17 | Boehringer Ingelheim International Gmbh | Multi-specific binding proteins for cancer treatment |
WO2019241426A1 (en) | 2018-06-13 | 2019-12-19 | Novartis Ag | Bcma chimeric antigen receptors and uses thereof |
WO2019246293A2 (en) | 2018-06-19 | 2019-12-26 | Atarga, Llc | Antibody molecules to complement component 5 and uses thereof |
WO2020010250A2 (en) | 2018-07-03 | 2020-01-09 | Elstar Therapeutics, Inc. | Anti-tcr antibody molecules and uses thereof |
US11845797B2 (en) | 2018-07-03 | 2023-12-19 | Marengo Therapeutics, Inc. | Anti-TCR antibody molecules and uses thereof |
DE202019005887U1 (en) | 2018-07-03 | 2023-06-14 | Marengo Therapeutics, Inc. | Anti-TCR antibody molecules and uses thereof |
WO2020012337A1 (en) | 2018-07-10 | 2020-01-16 | Novartis Ag | 3-(5-amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and their use in the treatment of i karos family zinc finger 2 (ikzf2)-dependent diseases |
WO2020021465A1 (en) | 2018-07-25 | 2020-01-30 | Advanced Accelerator Applications (Italy) S.R.L. | Method of treatment of neuroendocrine tumors |
US11046769B2 (en) | 2018-11-13 | 2021-06-29 | Compass Therapeutics Llc | Multispecific binding constructs against checkpoint molecules and uses thereof |
WO2020128898A1 (en) | 2018-12-20 | 2020-06-25 | Novartis Ag | Pharmaceutical combinations |
WO2020128972A1 (en) | 2018-12-20 | 2020-06-25 | Novartis Ag | Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives |
WO2020165834A1 (en) | 2019-02-15 | 2020-08-20 | Novartis Ag | Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
WO2020165868A1 (en) | 2019-02-15 | 2020-08-20 | Perkinelmer Cellular Technologies Germany Gmbh | Low-power microscope-objective pre-scan and high-power microscope-objective scan in x,y and z-direction for imaging objects such as cells using a microscope |
WO2020165833A1 (en) | 2019-02-15 | 2020-08-20 | Novartis Ag | 3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
WO2020172598A1 (en) | 2019-02-21 | 2020-08-27 | Elstar Therapeutics, Inc. | Multifunctional molecules that bind to t cells and uses thereof to treat autoimmune disorders |
WO2020172596A1 (en) | 2019-02-21 | 2020-08-27 | Elstar Therapeutics, Inc. | Anti-tcr antibody molecules and thereof |
WO2020172605A1 (en) | 2019-02-21 | 2020-08-27 | Elstar Therapeutics, Inc. | Antibody molecules that bind to nkp30 and uses thereof |
WO2020172571A1 (en) | 2019-02-21 | 2020-08-27 | Elstar Therapeutics, Inc. | Multifunctional molecules that bind to t cell related cancer cells and uses thereof |
WO2020172601A1 (en) | 2019-02-21 | 2020-08-27 | Elstar Therapeutics, Inc. | Multifunctional molecules that bind to calreticulin and uses thereof |
WO2020172553A1 (en) | 2019-02-22 | 2020-08-27 | Novartis Ag | Combination therapies of egfrviii chimeric antigen receptors and pd-1 inhibitors |
WO2020205523A1 (en) | 2019-03-29 | 2020-10-08 | Atarga, Llc | Anti fgf23 antibody |
RU2807346C2 (en) * | 2019-07-11 | 2023-11-14 | УХАНЬ АйЗиАй БАЙОФАРМА КО., ЛТД. | Tetravalent symmetrical bispecific antibodies |
WO2021079188A1 (en) | 2019-10-21 | 2021-04-29 | Novartis Ag | Combination therapies with venetoclax and tim-3 inhibitors |
WO2021079195A1 (en) | 2019-10-21 | 2021-04-29 | Novartis Ag | Tim-3 inhibitors and uses thereof |
WO2021108661A2 (en) | 2019-11-26 | 2021-06-03 | Novartis Ag | Chimeric antigen receptors and uses thereof |
WO2021123996A1 (en) | 2019-12-20 | 2021-06-24 | Novartis Ag | Uses of anti-tgf-beta antibodies and checkpoint inhibitors for the treatment of proliferative diseases |
WO2021123902A1 (en) | 2019-12-20 | 2021-06-24 | Novartis Ag | Combination of anti tim-3 antibody mbg453 and anti tgf-beta antibody nis793, with or without decitabine or the anti pd-1 antibody spartalizumab, for treating myelofibrosis and myelodysplastic syndrome |
WO2021138407A2 (en) | 2020-01-03 | 2021-07-08 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to cd33 and uses thereof |
WO2021144657A1 (en) | 2020-01-17 | 2021-07-22 | Novartis Ag | Combination comprising a tim-3 inhibitor and a hypomethylating agent for use in treating myelodysplastic syndrome or chronic myelomonocytic leukemia |
WO2021146636A1 (en) | 2020-01-17 | 2021-07-22 | Becton, Dickinson And Company | Methods and compositions for single cell secretomics |
WO2021173995A2 (en) | 2020-02-27 | 2021-09-02 | Novartis Ag | Methods of making chimeric antigen receptor-expressing cells |
WO2021217085A1 (en) | 2020-04-24 | 2021-10-28 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to t cell related cancer cells and uses thereof |
WO2021260528A1 (en) | 2020-06-23 | 2021-12-30 | Novartis Ag | Dosing regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives |
WO2022013787A1 (en) | 2020-07-16 | 2022-01-20 | Novartis Ag | Anti-betacellulin antibodies, fragments thereof, and multi-specific binding molecules |
WO2022026592A2 (en) | 2020-07-28 | 2022-02-03 | Celltas Bio, Inc. | Antibody molecules to coronavirus and uses thereof |
WO2022029573A1 (en) | 2020-08-03 | 2022-02-10 | Novartis Ag | Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
WO2022046920A2 (en) | 2020-08-26 | 2022-03-03 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to calreticulin and uses thereof |
WO2022047046A1 (en) | 2020-08-26 | 2022-03-03 | Marengo Therapeutics, Inc. | Methods of detecting trbc1 or trbc2 |
WO2022046922A2 (en) | 2020-08-26 | 2022-03-03 | Marengo Therapeutics, Inc. | Antibody molecules that bind to nkp30 and uses thereof |
WO2022043557A1 (en) | 2020-08-31 | 2022-03-03 | Advanced Accelerator Applications International Sa | Method of treating psma-expressing cancers |
WO2022043558A1 (en) | 2020-08-31 | 2022-03-03 | Advanced Accelerator Applications International Sa | Method of treating psma-expressing cancers |
WO2022097065A2 (en) | 2020-11-06 | 2022-05-12 | Novartis Ag | ANTIBODY Fc VARIANTS |
WO2022104061A1 (en) | 2020-11-13 | 2022-05-19 | Novartis Ag | Combination therapies with chimeric antigen receptor (car)-expressing cells |
WO2022162569A1 (en) | 2021-01-29 | 2022-08-04 | Novartis Ag | Dosage regimes for anti-cd73 and anti-entpd2 antibodies and uses thereof |
WO2022215011A1 (en) | 2021-04-07 | 2022-10-13 | Novartis Ag | USES OF ANTI-TGFβ ANTIBODIES AND OTHER THERAPEUTIC AGENTS FOR THE TREATMENT OF PROLIFERATIVE DISEASES |
WO2022216993A2 (en) | 2021-04-08 | 2022-10-13 | Marengo Therapeutics, Inc. | Multifuntional molecules binding to tcr and uses thereof |
WO2022243846A1 (en) | 2021-05-18 | 2022-11-24 | Novartis Ag | Combination therapies |
WO2023044483A2 (en) | 2021-09-20 | 2023-03-23 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of her2 positive cancer |
WO2023092004A1 (en) | 2021-11-17 | 2023-05-25 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of tau-related disorders |
WO2023150778A1 (en) | 2022-02-07 | 2023-08-10 | Visterra, Inc. | Anti-idiotype antibody molecules and uses thereof |
WO2023209568A1 (en) | 2022-04-26 | 2023-11-02 | Novartis Ag | Multispecific antibodies targeting il-13 and il-18 |
WO2023220695A2 (en) | 2022-05-13 | 2023-11-16 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of her2 positive cancer |
WO2024030976A2 (en) | 2022-08-03 | 2024-02-08 | Voyager Therapeutics, Inc. | Compositions and methods for crossing the blood brain barrier |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1995009917A1 (en) | Genetically engineered bispecific tetravalent antibodies | |
AU702184B2 (en) | Immunoconjugates II | |
Shan et al. | Characterization of scFv-Ig constructs generated from the anti-CD20 mAb 1F5 using linker peptides of varying lengths | |
US5650150A (en) | Recombinant antibody cytokine fusion proteins | |
US5892019A (en) | Production of a single-gene-encoded immunoglobulin | |
Eldin et al. | High-level secretion of two antibody single chain Fv fragments by Pichia pastoris | |
US6071515A (en) | Dimer and multimer forms of single chain polypeptides | |
AU654811B2 (en) | Chimeric antibodies with receptor binding ligands in place of their constant region | |
EP0574395B1 (en) | Cytokine immunoconjugates | |
Coloma et al. | Design and production of novel tetravalent bispecific antibodies | |
Shalaby et al. | Development of humanized bispecific antibodies reactive with cytotoxic lymphocytes and tumor cells overexpressing the HER2 protooncogene. | |
Gillies et al. | Biological activity and in vivo clearance of anti-tumor antibody/cytokine fusion proteins | |
US5576184A (en) | Production of chimeric mouse-human antibodies with specificity to human tumor antigens | |
Cochlovius et al. | Treatment of human B cell lymphoma xenografts with a CD3× CD19 diabody and T cells | |
CA2069960C (en) | Bispecific heteroantibodies with dual effector functions | |
JPH07501698A (en) | Bivalent specific heterodimer | |
CA2110799A1 (en) | Microbially-produced antibody fragments and their conjugates | |
EP0325262A2 (en) | Cloned genes encoding IG-CD4 fusion proteins and the use thereof | |
Libyh et al. | A recombinant human scFv anti-Rh (D) antibody with multiple valences using a C-terminal fragment of C4-binding protein | |
Hu et al. | A chimeric Lym-1/interleukin 2 fusion protein for increasing tumor vascular permeability and enhancing antibody uptake | |
De Jonge et al. | In vivo retargeting of T cell effector function by recombinant bispecific single chain Fv (anti-CD3× anti-idiotype) induces long-term survival in the murine BCL1 lymphoma model | |
EP0203403B1 (en) | A cloned t cell capable of recognizing tumors and a t cell antigen receptor | |
Penichet et al. | Antibody-IL-2 fusion proteins: a novel strategy for immune potentiation | |
Shin et al. | Hybrid antibodies | |
JPH05304987A (en) | Human type monoclonal antibody and gene coding the same, hybridoma and antitumor agent |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): CA JP |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: CA |